Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1981 2
1982 3
1983 9
1984 17
1985 16
1986 25
1987 20
1988 26
1989 31
1990 26
1991 29
1992 27
1993 30
1994 30
1995 37
1996 32
1997 39
1998 42
1999 47
2000 43
2001 72
2002 55
2003 63
2004 133
2005 88
2006 120
2007 134
2008 187
2009 222
2010 256
2011 332
2012 337
2013 335
2014 362
2015 346
2016 362
2017 337
2018 335
2019 437
2020 485
2021 447
2022 462
2023 443
2024 170

Text availability

Article attribute

Article type

Publication date

Search Results

6,349 results

Results by year

Filters applied: Free full text. Clear all
Page 1
Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis.
Chen S, Huang M, Zhang L, Huang Q, Wang Y, Liang Y. Chen S, et al. Comput Struct Biotechnol J. 2023 Dec 6;23:369-383. doi: 10.1016/j.csbj.2023.12.001. eCollection 2024 Dec. Comput Struct Biotechnol J. 2023. PMID: 38226313 Free PMC article.
During sub-group analysis, area under the curve (AUC) values of 0.82, 0.80, 0.71, 0.7, 0.67, and 0.64 were obtained for the non-small cell lung cancer, gastric cancer, metastatic urothelial cancer, primary bladder cancer, metastatic melanoma, and renal …
During sub-group analysis, area under the curve (AUC) values of 0.82, 0.80, 0.71, 0.7, 0.67, and 0.64 were obtained for the non-small cell l …
Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model.
Kuryk L, Mathlouthi S, Wieczorek M, Gad B, Rinner B, Malfanti A, Mastrotto F, Salmaso S, Caliceti P, Garofalo M. Kuryk L, et al. Eur J Pharm Biopharm. 2024 Jun;199:114300. doi: 10.1016/j.ejpb.2024.114300. Epub 2024 Apr 30. Eur J Pharm Biopharm. 2024. PMID: 38697488 Free article.
Triple-negative breast cancer (TNBC) is considered one of the most incurable malignancies due to its clinical characteristics, including high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. ...Importantly, sequential administration …
Triple-negative breast cancer (TNBC) is considered one of the most incurable malignancies due to its clinical characteristics, …
Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab.
Bergamini C, Niro L, Springhetti P, Ferri L, Trento L, Minnucci I, Maffeis C, Tafciu E, Rossi A, Fiorio E, Benfari G, Ribichini F. Bergamini C, et al. Cardiovasc Toxicol. 2024 Jun;24(6):550-562. doi: 10.1007/s12012-024-09861-6. Epub 2024 May 2. Cardiovasc Toxicol. 2024. PMID: 38696070 Free PMC article.
Trastuzumab is widely used in HER2 breast cancer. However, it may cause left ventricular (LV) dysfunction. ...The aim of this study is exploring the relationship between early changes in left atrial function and the development of Trastuzumab-induced cardiotoxicity. …
Trastuzumab is widely used in HER2 breast cancer. However, it may cause left ventricular (LV) dysfunction. ...The aim of this …
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Ginzac A, Molnar I, Durando X, Motte Rouge T, Petit T, D'hondt V, Campone M, Bonichon-Lamichhane N, Venat Bouvet L, Levy C, Augereau P, Pistilli B, Arsene O, Jouannaud C, Nguyen S, Cayre A, Tixier L, Mahier Ait Oukhatar C, Nabholtz JM, Penault-Llorca F, Mouret-Reynier MA. Ginzac A, et al. Breast Cancer Res Treat. 2024 Jun;205(2):267-279. doi: 10.1007/s10549-024-07285-y. Epub 2024 Mar 7. Breast Cancer Res Treat. 2024. PMID: 38453781 Free PMC article. Clinical Trial.
PURPOSE: Previous studies have reported the benefit of dual HER2-targeting combined to neoadjuvant chemotherapy in HER2-amplified breast cancer (HER2 + BC). Moreover, besides the cardiac toxicity following their association to Trastuzumab, anthracyclines chemotherap …
PURPOSE: Previous studies have reported the benefit of dual HER2-targeting combined to neoadjuvant chemotherapy in HER2-amplified breast
Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.
Geurts SME, Ibragimova KIE, Ding N, Meegdes M, Erdkamp F, Heijns JB, Tol J, Vriens BEPJ, Dercksen MW, Aaldering KNA, Pepels MJAE, van de Winkel L, Peters NAJB, van de Wouw AJ, Maaskant SAJG, Teeuwen-Dedroog NJA, van Nijnatten TJA, de Boer M, Tjan-Heijnen VCG. Geurts SME, et al. Breast Cancer Res Treat. 2024 Jun;205(2):287-302. doi: 10.1007/s10549-023-07235-0. Epub 2024 Feb 21. Breast Cancer Res Treat. 2024. PMID: 38381274 Free PMC article.
PURPOSE: The aim was to determine whether the real-world first-line progression-free survival (PFS) of patients diagnosed with de novo human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer (ABC) has improved since the introduction of pertu …
PURPOSE: The aim was to determine whether the real-world first-line progression-free survival (PFS) of patients diagnosed with de novo human …
A Case of Anti-Ma2 Encephalitis Presenting with Pendular Torsional Nystagmus.
Vaghi G, Vegezzi E, Bini P, Gastaldi M, Diamanti L, Marchioni E, Colnaghi S. Vaghi G, et al. Cerebellum. 2024 Jun;23(3):1249-1253. doi: 10.1007/s12311-023-01601-w. Epub 2023 Oct 18. Cerebellum. 2024. PMID: 37848701 Free PMC article.
Antibodies against the neuronal protein Ma2 have been reported in a peculiar form of paraneoplastic encephalitis with prominent involvement of the limbic, brainstem, and diencephalic structures and usually associated with germ cell testicular, lung, or breast can
Antibodies against the neuronal protein Ma2 have been reported in a peculiar form of paraneoplastic encephalitis with prominent invol
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
Kuemmel S, Harper-Wynne C, Park YH, Franke F, de Laurentiis M, Schumacher-Wulf E, Eiger D, Heeson S, Cardona A, Özyilkan Ö, Morales-Vàsquez F, Metcalfe C, Hafner M, Restuccia E, O'Shaughnessy J. Kuemmel S, et al. BMC Cancer. 2024 May 24;24(1):641. doi: 10.1186/s12885-024-12179-9. BMC Cancer. 2024. PMID: 38789924 Free PMC article. Clinical Trial.
BACKGROUND: HER2-positive, estrogen receptor-positive breast cancer (HER2+, ER+ BC) is a distinct disease subtype associated with inferior response to chemotherapy plus HER2-targeted therapy compared with HER2+, ER-negative BC. ...
BACKGROUND: HER2-positive, estrogen receptor-positive breast cancer (HER2+, ER+ BC) is a distinct disease subtype associated w …
Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
Khoirunnisa SM, Suryanegara FDA, Setiawan D, Postma MJ, de Jong LA. Khoirunnisa SM, et al. PLoS One. 2024 May 24;19(5):e0304483. doi: 10.1371/journal.pone.0304483. eCollection 2024. PLoS One. 2024. PMID: 38787899 Free PMC article.
BACKGROUND: Trastuzumab has significantly enhanced the survival and prognosis of individuals diagnosed with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Considering its relatively high costs, we aimed to examine the cost-effectivenes …
BACKGROUND: Trastuzumab has significantly enhanced the survival and prognosis of individuals diagnosed with human epidermal growth factor re …
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA. Bardia A, et al. J Clin Oncol. 2024 May 20;42(15):1738-1744. doi: 10.1200/JCO.23.01409. Epub 2024 Feb 29. J Clin Oncol. 2024. PMID: 38422473 Free PMC article. Clinical Trial.
Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Sacituzumab govitecan (SG), a first-in-class anti-trophoblast cell surface antigen 2 (Trop-2) ant …
Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the p …
"Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper".
Conte P, Ciruelos E, Curigliano G, De Laurentiis M, Del Mastro L, Gennari A, Llombart A, Martìn M, Poggio F, Prat A, Puglisi F, Saura C. Conte P, et al. Breast. 2024 May 16;76:103742. doi: 10.1016/j.breast.2024.103742. Online ahead of print. Breast. 2024. PMID: 38772190 Free article.
INTRODUCTION: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2-positive breast cancer patients. Despite the expanding treatment options and clinica …
INTRODUCTION: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) have nota …
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment.
Bardakci M, Karakas H, Bayram D, Avci N, Kitapli S, Ozen M, Aslan F, Koseoglu C, Kadioglu A, Onur ID, Sakalar T, Buyuksimsek M, Alkan A, Ergun Y, Kaya AO, Bilgin B, Yalcin B. Bardakci M, et al. Sci Rep. 2024 May 9;14(1):10632. doi: 10.1038/s41598-024-61562-w. Sci Rep. 2024. PMID: 38724585 Free PMC article.
While some clinics have adopted abbreviated neoadjuvant treatment for HER2-positive breast cancer, there remains a shortage of comprehensive clinical data to support this practice. ...This study supports shortened neoadjuvant treatment of HER2-positive breast
While some clinics have adopted abbreviated neoadjuvant treatment for HER2-positive breast cancer, there remains a shortage of …
Early therapy evaluation of intra-arterial trastuzumab injection in a human breast cancer xenograft model using multiparametric MR imaging.
Kim BK, Kim B, You SH, Jang MS, Im GH, Kim KH. Kim BK, et al. PLoS One. 2024 May 3;19(5):e0300171. doi: 10.1371/journal.pone.0300171. eCollection 2024. PLoS One. 2024. PMID: 38701062 Free PMC article.
PURPOSE: To investigate the treatment efficacy of intra-arterial (IA) trastuzumab treatment using multiparametric magnetic resonance imaging (MRI) in a human breast cancer xenograft model. MATERIALS AND METHODS: Human breast cancer cells (BT474) were s …
PURPOSE: To investigate the treatment efficacy of intra-arterial (IA) trastuzumab treatment using multiparametric magnetic resonance imaging …
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer.
Gedik ME, Saatci O, Oberholtzer N, Uner M, Akbulut Caliskan O, Cetin M, Aras M, Ibis K, Caliskan B, Banoglu E, Wiemann S, Üner A, Aksoy S, Mehrotra S, Sahin O. Gedik ME, et al. Cancer Res. 2024 May 2;84(9):1475-1490. doi: 10.1158/0008-5472.CAN-23-2812. Cancer Res. 2024. PMID: 38319231 Free PMC article.
Trastuzumab emtansine (T-DM1) was the first and one of the most successful antibody-drug conjugates (ADC) approved for treating refractory HER2-positive breast cancer. Despite its initial clinical efficacy, resistance is unfortunately common, necessitating approache …
Trastuzumab emtansine (T-DM1) was the first and one of the most successful antibody-drug conjugates (ADC) approved for treating refractory H …
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Egorov A, Liu Y, Cathcart J, Bako E, Tecson K, Verma S, Cortés J. Hurvitz SA, et al. ESMO Open. 2024 May;9(5):102924. doi: 10.1016/j.esmoop.2024.102924. Epub 2024 Apr 24. ESMO Open. 2024. PMID: 38796287 Free article. Clinical Trial.
BACKGROUND: DESTINY-Breast03 is a randomized, multicenter, open-label, phase III study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) pre …
BACKGROUND: DESTINY-Breast03 is a randomized, multicenter, open-label, phase III study of trastuzumab deruxtecan (T-DXd) versus trastuzumab …
Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
Man X, Huang J, Sun S, Zhou D, Zhang B, Fang S, Zheng F, Li C, Wang X, Huang W, Wang L, He Q, Fu H, Zhang Y, Liu C, Dong L, Zhao X, Xu L, Sun X, Fan B, Song L, Zhou Z, Yu J, Li H. Man X, et al. Clin Transl Med. 2024 May;14(5):e1687. doi: 10.1002/ctm2.1687. Clin Transl Med. 2024. PMID: 38738791 Free PMC article. Clinical Trial.
OBJECTIVE: It has been observed that the prognosis of patients with HER2-positive metastatic breast cancer has improved significantly with HER2-targeted agents. ...METHODS: Patients who have received adjuvant and/or neoadjuvant trastuzumab for HER2-positive metastat …
OBJECTIVE: It has been observed that the prognosis of patients with HER2-positive metastatic breast cancer has improved signif …
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T, Hajjaji N, Antoine EC, Benderra MA, Gozy M, Foa C, Mouysset JL, Grenier J, Mousseau M, Mailliez A, Saghatchian M, Lachaier E, Desmoulins I, Hennequin A, Maes P, Loirat D, Ricci F, Diéras V, Berton D, Tiong FL, Teixeira L, Dohollou N, Lévy C, Bachelot T, Pierga JY. Petit T, et al. Cancer Med. 2024 May;13(9):e7168. doi: 10.1002/cam4.7168. Cancer Med. 2024. PMID: 38733172 Free PMC article.
BACKGROUND: Early access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T-DXd) in France based on DESTINY-Breast01 trial which demonstrated its efficacy and safety in HER2-positive metastatic/unresectable breast cancer
BACKGROUND: Early access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T-DXd) in France …
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab.
Buisseret L, Bareche Y, Venet D, Girard E, Gombos A, Emonts P, Majjaj S, Rouas G, Serra M, Debien V, Agostinetto E, Garaud S, Willard-Gallo K, Larsimont D, Stagg J, Rothé F, Sotiriou C. Buisseret L, et al. ESMO Open. 2024 May;9(5):102964. doi: 10.1016/j.esmoop.2024.102964. Epub 2024 May 3. ESMO Open. 2024. PMID: 38703428 Free PMC article.
BACKGROUND: Immune checkpoint blockade (ICB) in combination with chemotherapy improves outcome of patients with triple-negative breast cancer (TNBC) in metastatic and early settings. The identification of predictive biomarkers able to guide treatment decisions is ch …
BACKGROUND: Immune checkpoint blockade (ICB) in combination with chemotherapy improves outcome of patients with triple-negative breast
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T, Cottone F, Dunton K, André F, Krop I, Park YH, De Laurentiis M, Miyoshi Y, Armstrong A, Borrego MR, Yerushalmi R, Duhoux FP, Takano T, Lu W, Egorov A, Kim SB. Fehm T, et al. Lancet Oncol. 2024 May;25(5):614-625. doi: 10.1016/S1470-2045(24)00128-1. Lancet Oncol. 2024. PMID: 38697155 Free article. Clinical Trial.
BACKGROUND: In DESTINY-Breast02, patients with HER2-positive unresectable or metastatic breast cancer who received trastuzumab deruxtecan demonstrated superior progression-free and overall survival compared with those receiving treatment of physician's choice. ...PR …
BACKGROUND: In DESTINY-Breast02, patients with HER2-positive unresectable or metastatic breast cancer who received trastuzumab …
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.
Cecco S, Puligheddu S, Fusaroli M, Gerratana L, Yan M, Zamagni C, De Ponti F, Raschi E. Cecco S, et al. Target Oncol. 2024 May;19(3):435-445. doi: 10.1007/s11523-024-01058-9. Epub 2024 May 2. Target Oncol. 2024. PMID: 38696126 Free PMC article.
BACKGROUND: Antibody-drug conjugates (ADCs) are gaining widespread use in the treatment of breast cancer, although toxicity remains an underexplored issue in the real-world clinical setting. ...OBJECTIVE: We prioritized adverse events (AEs) reported with ADCs approv …
BACKGROUND: Antibody-drug conjugates (ADCs) are gaining widespread use in the treatment of breast cancer, although toxicity re …
Pembrolizumab response in stage IV luminal-type breast cancer with high microsatellite instability: a case report.
Inakami K, Fujita N, Iguchi C, Enomoto Y, Minohata J, Sata A, Miyagawa Y, Yanagisawa T, Saitoh T, Nomura T, Sawai Y, Takahara K, Kasugai T, Shiba E. Inakami K, et al. J Med Case Rep. 2024 May 1;18(1):214. doi: 10.1186/s13256-024-04522-2. J Med Case Rep. 2024. PMID: 38689362 Free PMC article.
However, patients with breast cancer rarely have MSI-High, the use of PEM in such cases in clinical practice is uncertain due to lack of sufficient supporting data. Here, we report the case of a premenopausal woman in who received PEM for MSI-High luminal-type br
However, patients with breast cancer rarely have MSI-High, the use of PEM in such cases in clinical practice is uncertain due …
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
Dannehl D, Jakob D, Mergel F, Estler A, Engler T, Volmer L, Frevert ML, Matovina S, Englisch A, Tegeler CM, Rohner A, Seller A, Hahn M, Pfister K, Fink A, Popp I, Lorenz S, Tabatabai G, Juhasz-Böss I, Janni W, Brucker S, Taran FA, Hartkopf A, Schäffler H. Dannehl D, et al. ESMO Open. 2024 May;9(5):102995. doi: 10.1016/j.esmoop.2024.102995. Epub 2024 Apr 17. ESMO Open. 2024. PMID: 38636292 Free PMC article.
BACKGROUND: Fifteen to thirty percent of all patients with metastatic breast cancer (MBC) develop brain metastases (BCBMs). Recently, the antibody-drug conjugates (ADCs) sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have shown to be highly effective …
BACKGROUND: Fifteen to thirty percent of all patients with metastatic breast cancer (MBC) develop brain metastases (BCBMs). Re …
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.
Sathe AG, Singh I, Singh P, Diderichsen PM, Wang X, Chang P, Taqui A, Phan S, Girish S, Othman AA. Sathe AG, et al. Clin Pharmacokinet. 2024 May;63(5):669-681. doi: 10.1007/s40262-024-01366-3. Epub 2024 Apr 5. Clin Pharmacokinet. 2024. PMID: 38578394 Free PMC article. Clinical Trial.
SG is approved for patients with metastatic triple-negative breast cancer (mTNBC) who have received two or more prior chemotherapies (at least one in a metastatic setting) and for patients with pretreated hormone receptor positive (HR+)/human epidermal growth factor …
SG is approved for patients with metastatic triple-negative breast cancer (mTNBC) who have received two or more prior chemothe …
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.
Staropoli N, Scionti F, Farenza V, Falcone F, Luciano F, Renne M, Di Martino MT, Ciliberto D, Tedesco L, Crispino A, Labanca C, Cucè M, Esposito S, Agapito G, Cannataro M, Tassone P, Tagliaferri P, Arbitrio M. Staropoli N, et al. Biomed Pharmacother. 2024 May;174:116478. doi: 10.1016/j.biopha.2024.116478. Epub 2024 Mar 27. Biomed Pharmacother. 2024. PMID: 38547766 Free article.
BACKGROUND: Long-term survival induced by anticancer treatments discloses emerging frailty among breast cancer (BC) survivors. Trastuzumab-induced cardiotoxicity (TIC) is reported in at least 5% of HER2+BC patients. ...Interaction between systemic inflammation, cyto …
BACKGROUND: Long-term survival induced by anticancer treatments discloses emerging frailty among breast cancer (BC) survivors. …
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley KA, Venet D, Rashid NU, Spears PA, Islam MN, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huobe J, Goerlitz D, Hu R, Lucas PC, Swain SM, Sotiriou C, Perou CM, Carey LA. Fernandez-Martinez A, et al. JAMA Oncol. 2024 May 1;10(5):603-611. doi: 10.1001/jamaoncol.2023.7304. JAMA Oncol. 2024. PMID: 38546612 Free PMC article.
IMPORTANCE: Biologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plus ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer (EBC). OBJECTIVE: To define the quantitative association betw …
IMPORTANCE: Biologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plu …
Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
Yang L, Bhattacharya A, Peterson D, Li Y, Liu X, Marangoni E, Robila V, Zhang Y. Yang L, et al. Drug Resist Updat. 2024 May;74:101078. doi: 10.1016/j.drup.2024.101078. Epub 2024 Mar 13. Drug Resist Updat. 2024. PMID: 38503142 Free article.
AIMS: Human epidermal growth factor receptor 2 (HER2) is an oncogenic receptor tyrosine kinase amplified in approximately 20% of breast cancer (BC). HER2-targeted therapies are the linchpin of treating HER2-positive BC. ...The findings provide new insights and innov …
AIMS: Human epidermal growth factor receptor 2 (HER2) is an oncogenic receptor tyrosine kinase amplified in approximately 20% of breast
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez PA, Schlaepfer MI, Del Puerto-Nevado L, Aguilera O, García-García L, Galeano C, de Miguel I, Serrano-López J, Baños N, Fernández-Aceñero MJ, Lacal JC, Medico E, García-Foncillas J, Cebrián A. Rio-Vilariño A, et al. Br J Cancer. 2024 May;130(8):1402-1413. doi: 10.1038/s41416-024-02649-z. Epub 2024 Mar 11. Br J Cancer. 2024. PMID: 38467828 Free PMC article.
BACKGROUND: Primary resistance to anti-EGFR therapies affects 40% of metastatic colorectal cancer patients harbouring wild-type RAS/RAF. YAP1 activation is associated with this resistance, prompting an investigation into AURKA's role in mediating YAP1 phosphorylation at Se …
BACKGROUND: Primary resistance to anti-EGFR therapies affects 40% of metastatic colorectal cancer patients harbouring wild-type RAS/R …
Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2-Positive Breast Cancer.
Duan N, Hua Y, Yan X, He Y, Zeng T, Gong J, Fu Z, Li W, Yin Y. Duan N, et al. Adv Sci (Weinh). 2024 May;11(18):e2309424. doi: 10.1002/advs.202309424. Epub 2024 Mar 9. Adv Sci (Weinh). 2024. PMID: 38460162 Free PMC article.
Secondary trastuzumab resistance represents an evolutionary adaptation of HER2-positive breast cancer during anti-HER2 treatment. Most current studies have tended to prioritize HER2 and its associated signaling pathways, often overlooking broader but seemingly less …
Secondary trastuzumab resistance represents an evolutionary adaptation of HER2-positive breast cancer during anti-HER2 treatme …
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, Yoshida M, Sakatani T, Sasaki E, Tanabe Y, Tsurutani J, Takano T, Saji S, Masuda S, Horii R, Tsuda H, Yamaguchi R, Toyama T, Yamauchi C, Toi M, Yamamoto Y. Hattori M, et al. Breast Cancer. 2024 May;31(3):335-339. doi: 10.1007/s12282-024-01550-0. Epub 2024 Mar 4. Breast Cancer. 2024. PMID: 38433181 Free PMC article.
The Japanese Breast Cancer Society Clinical Practice Guidelines are published as timely guidance on clinical issues in breast cancer treatment in Japan. In the recent edition of these guidelines, we addressed a new clinical question 34 (CQ 34, systemic …
The Japanese Breast Cancer Society Clinical Practice Guidelines are published as timely guidance on clinical issues in brea
Ravulizumab in myasthenic crisis: the first case report.
Konen FF, Jendretzky KF, Ratuszny D, Schuppner R, Sühs KW, Pawlitzki M, Ruck T, Meuth SG, Skripuletz T. Konen FF, et al. J Neurol. 2024 May;271(5):2898-2901. doi: 10.1007/s00415-024-12234-2. Epub 2024 Feb 23. J Neurol. 2024. PMID: 38388927 Free PMC article. No abstract available.
Effect of Osteoporosis Treatments on Osteoarthritis Progression in Postmenopausal Women: A Review of the Literature.
Ho WC, Chang CC, Wu WT, Lee RP, Yao TK, Peng CH, Yeh KT. Ho WC, et al. Curr Rheumatol Rep. 2024 May;26(5):188-195. doi: 10.1007/s11926-024-01139-8. Epub 2024 Feb 19. Curr Rheumatol Rep. 2024. PMID: 38372871 Free PMC article. Review.
Denosumab is approved to treat osteoporosis, bone metastases, and certain types of breast cancer, but little study has been done with respect to its effect on OA. ...
Denosumab is approved to treat osteoporosis, bone metastases, and certain types of breast cancer, but little study has been do …
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. DiPeri TP, et al. Cancer Discov. 2024 May 1;14(5):828-845. doi: 10.1158/2159-8290.CD-23-0838. Cancer Discov. 2024. PMID: 38358339 Free PMC article. Clinical Trial.
Anti-HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone-Fused Enediyne.
Feng X, Wen Z, Zhu X, Yan X, Duan Y, Huang Y. Feng X, et al. Adv Sci (Weinh). 2024 May;11(17):e2307865. doi: 10.1002/advs.202307865. Epub 2024 Feb 14. Adv Sci (Weinh). 2024. PMID: 38355309 Free PMC article.
This study not only provides a straightforward method for the effective delivery of TNM A against HER2-positive breast tumors but also underscores the potential of IL-based drug delivery systems when employing highly potent cytotoxins as payloads....
This study not only provides a straightforward method for the effective delivery of TNM A against HER2-positive breast tumors but als …
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.
Verschoor N, Bos MK, de Kruijff IE, Van MN, Kraan J, Drooger JC, Zuetenhorst JM, Wilting SM, Sleijfer S, Jager A, Martens JWM. Verschoor N, et al. Breast Cancer Res Treat. 2024 May;205(1):87-95. doi: 10.1007/s10549-023-07231-4. Epub 2024 Jan 31. Breast Cancer Res Treat. 2024. PMID: 38291268 Free PMC article. Clinical Trial.
PURPOSE: HER2 overexpressing circulating tumor cells (CTCs) are observed in up to 25% of HER2-negative metastatic breast cancer patients. Since targeted anti-HER2 therapy has drastically improved clinical outcomes of patients with HER2-positive breast canc
PURPOSE: HER2 overexpressing circulating tumor cells (CTCs) are observed in up to 25% of HER2-negative metastatic breast cancer
A new fluorescenttargeting tracer contrasts dual tracers in sentinel lymph node biopsy of breast cancer.
Wu S, Li P, Zhang Q, Sun X, Cong B, Wang Y. Wu S, et al. Future Oncol. 2024 May;20(14):951-958. doi: 10.2217/fon-2021-1152. Epub 2023 Nov 29. Future Oncol. 2024. PMID: 38018441 Free article.
Purpose: To explore the clinical application value of indocyanine green (ICG)-rituximab in sentinel lymph node biopsy. Methods: This study included 156 patients with primary breast cancer: 50 patients were enrolled in dose-climbing test, and 106 patients were enroll …
Purpose: To explore the clinical application value of indocyanine green (ICG)-rituximab in sentinel lymph node biopsy. Methods: This study i …
Denosumab-related osteonecrosis of the external auditory canal-benefit of the early surgical management.
Peřina V, Salzman R, Treglerová J. Peřina V, et al. Ear Nose Throat J. 2024 May;103(5):277-281. doi: 10.1177/01455613211053389. Epub 2021 Oct 21. Ear Nose Throat J. 2024. PMID: 34672841 Free article.
Here, we provide a case of denosumab-related osteonecrosis of the external auditory canal successfully treated surgically in the early stage of the disease. Case report: A 68-year-old patient with breast cancer underwent comprehensive oncological treatment, includin …
Here, we provide a case of denosumab-related osteonecrosis of the external auditory canal successfully treated surgically in the early stage …
From standard therapies to monoclonal antibodies and immune checkpoint inhibitors - an update for reconstructive surgeons on common oncological cases.
Knoedler L, Huelsboemer L, Hollmann K, Alfertshofer M, Herfeld K, Hosseini H, Boroumand S, Stoegner VA, Safi AF, Perl M, Knoedler S, Pomahac B, Kauke-Navarro M. Knoedler L, et al. Front Immunol. 2024 Apr 23;15:1276306. doi: 10.3389/fimmu.2024.1276306. eCollection 2024. Front Immunol. 2024. PMID: 38715609 Free PMC article. Review.
In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and immune checkpoint inhibitors (ICI) have been successfully incorporated into standard treatment algorithms. ...However, the in-toto surgical tumor resection follow …
In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and immune checkpoint inhi …
Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
Zhang C, Liu Y, Jiang J, Chen C, Duan Z, Su H, Wang S, Tian B, Shi Y, Xiang R, Luo Y. Zhang C, et al. Theranostics. 2024 Apr 22;14(7):2757-2776. doi: 10.7150/thno.94537. eCollection 2024. Theranostics. 2024. PMID: 38773982 Free PMC article.
Monoclonal antibodies that antagonize the "don't-eat-me" signaling in macrophages and tumor cells by targeting phagocytic checkpoints have shown therapeutic promises in several cancer types. ...Then, in vivo experiments in mouse models were conducted to explo
Monoclonal antibodies that antagonize the "don't-eat-me" signaling in macrophages and tumor cells by targeting phagocytic chec
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Breast Cancer Res. 2024 Apr 22;26(1):69. doi: 10.1186/s13058-024-01823-8. Breast Cancer Res. 2024. PMID: 38650031 Free PMC article. Clinical Trial.
BACKGROUND: We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more durable responses. ...
BACKGROUND: We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive …
DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X, Yao J, Qu C, Luo L, Li B, Zhang Y, Zhu Z, Qiu Y, Hua H. Li X, et al. J Transl Med. 2024 Apr 17;22(1):362. doi: 10.1186/s12967-024-05133-7. J Transl Med. 2024. PMID: 38632563 Free PMC article.
In vivo growth inhibition study evaluated the sensitivity of DB-1310 to Her3 + breast, lung, colon and prostate cancer xenograft models. The safety profile was also measured in cynomolgus monkey. ...In vitro, DB-1310 exhibited cytotoxicity in numerous HER3 + brea
In vivo growth inhibition study evaluated the sensitivity of DB-1310 to Her3 + breast, lung, colon and prostate cancer xenogra …
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases.
Angeli E, Paris J, Le Tilly O, Desvignes C, Gapihan G, Boquet D, Pamoukdjian F, Hamdan D, Rigal M, Poirier F, Lutomski D, Azibani F, Mebazaa A, Herbet A, Mabondzo A, Falgarone G, Janin A, Paintaud G, Bousquet G. Angeli E, et al. Exp Hematol Oncol. 2024 Apr 15;13(1):41. doi: 10.1186/s40164-024-00513-7. Exp Hematol Oncol. 2024. PMID: 38622749 Free PMC article.
Despite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause of death for women with metastatic HER2 breast cancer. The main reason is the limited drug passage of the …
Despite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations rem …
Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer.
Glen C, Morrow A, Roditi G, Hopkins T, Macpherson I, Stewart P, Petrie MC, Berry C, Epstein F, Lang NN, Mangion K. Glen C, et al. Heart. 2024 Apr 15;110(9):650-656. doi: 10.1136/heartjnl-2023-323437. Heart. 2024. PMID: 38103912 Free PMC article.
METHODS: Participants with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumabanthracycline 5 years previously were identified from a clinical database. ...Our findings reinforce the relevance of comprehensive evaluation of cardi …
METHODS: Participants with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumabanthracycli …
A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer.
Mineva ND, Pianetti S, Das SG, Srinivasan S, Billiald NM, Sonenshein GE. Mineva ND, et al. Pharmaceutics. 2024 Apr 13;16(4):536. doi: 10.3390/pharmaceutics16040536. Pharmaceutics. 2024. PMID: 38675197 Free PMC article.
New targeted treatments are urgently needed to improve triple-negative breast cancer (TNBC) patient survival. Previously, we identified the cell surface protein A Disintegrin And Metalloprotease 8 (ADAM8) as a driver of TNBC tumor growth and spread via its metallopr …
New targeted treatments are urgently needed to improve triple-negative breast cancer (TNBC) patient survival. Previously, we i …
Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer.
Zhang N, Huang Y, Wang G, Xiang Y, Jing Z, Zeng J, Yu F, Pan X, Zhou W, Zeng X. Zhang N, et al. Breast Cancer Res. 2024 Apr 12;26(1):64. doi: 10.1186/s13058-024-01813-w. Breast Cancer Res. 2024. PMID: 38610016 Free PMC article.
BACKGROUND: This study aimed to explore potential indicators associated with the neoadjuvant efficacy of TCbHP regimen (taxane, carboplatin, trastuzumab, and pertuzumab) in HER2 + breast cancer (BrCa) patients. METHODS: A total of 120 plasma samples from 40 patients …
BACKGROUND: This study aimed to explore potential indicators associated with the neoadjuvant efficacy of TCbHP regimen (taxane, carboplatin, …
Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer.
Liang B, Wu Q, Wang Y, Shi Y, Sun F, Huang Q, Li G, Liu Y, Zhang S, Xu X, Yao G, Peng J, Zhai X, Wu J, Tan Y, Wu Z, Zhou R, Li S, Wu J, Yang M, Liao W, Shi M. Liang B, et al. Cancer Lett. 2024 Apr 10;587:216702. doi: 10.1016/j.canlet.2024.216702. Epub 2024 Feb 8. Cancer Lett. 2024. PMID: 38336288 Free article.
Resistance to trastuzumab and the poor efficacy of subsequent chemotherapy have become major challenges for HER2-positive gastric cancer (GC). As resistance evolves, tumor cells may acquire a new drug susceptibility profile, profoundly impacting the subsequent treatment se …
Resistance to trastuzumab and the poor efficacy of subsequent chemotherapy have become major challenges for HER2-positive gastric cancer
Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China.
Peng DM, Li J, Qiu JX, Zhao L. Peng DM, et al. World J Surg Oncol. 2024 Apr 6;22(1):88. doi: 10.1186/s12957-024-03365-x. World J Surg Oncol. 2024. PMID: 38582875 Free PMC article.
INTRODUCTION: Real-world studies on neoadjuvant dual anti-HER2 therapy combined with chemotherapy for breast cancer (BC) are scarce in China. This study aimed to evaluate the efficacy and safety of neoadjuvant dual anti-HER2 therapy combined with chemotherapy in a r …
INTRODUCTION: Real-world studies on neoadjuvant dual anti-HER2 therapy combined with chemotherapy for breast cancer (BC) are s …
Respiratory viral infection promotes the awakening and outgrowth of dormant metastatic breast cancer cells in lungs.
Chia SB, Johnson BJ, Hu J, Vermeulen R, Chadeau-Hyam M, Guntoro F, Montgomery H, Boorgula MP, Sreekanth V, Goodspeed A, Davenport B, Pereira FV, Zaberezhnyy V, Schleicher WE, Gao D, Cadar AN, Papanicolaou M, Beheshti A, Baylin SB, Costello J, Bartley JM, Morrison TE, Aguirre-Ghiso JA, Rincon M, DeGregori J. Chia SB, et al. Res Sq [Preprint]. 2024 Apr 5:rs.3.rs-4210090. doi: 10.21203/rs.3.rs-4210090/v1. Res Sq. 2024. PMID: 38645169 Free PMC article. Preprint.
Breast cancer is the second most common cancer globally. Most deaths from breast cancer are due to metastatic disease which often follows long periods of clinical dormancy(1). ...Single-cell RNA-seq analyses reveal DCC-dependent impairment of T-
Breast cancer is the second most common cancer globally. Most deaths from breast cancer are due to metast
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Botticelli A, et al. Oncologist. 2024 Apr 4;29(4):303-310. doi: 10.1093/oncolo/oyad308. Oncologist. 2024. PMID: 37995313 Free PMC article.
BACKGROUND: Trastuzumab deruxtecan (T-DXd) demonstrated unprecedented efficacy in patients with pretreated HER2+ metastatic breast cancer (mBC). However, few data are available about its efficacy in routine clinical practice. ...
BACKGROUND: Trastuzumab deruxtecan (T-DXd) demonstrated unprecedented efficacy in patients with pretreated HER2+ metastatic breast
Baseline CD4(+) and expansion of gammadelta T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Uwe Blohmer J, Zahm DM, Jackisch C, Mackelenbergh MV, Thomalla J, Marmé F, Huober J, Müller V, Schem C, Müller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Denkert C, Seliger B. Massa C, et al. Clin Transl Med. 2024 Apr;14(4):e1617. doi: 10.1002/ctm2.1617. Clin Transl Med. 2024. PMID: 38664548 Free PMC article. No abstract available.
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Kuboki Y, Koyama T, Matsubara N, Naito Y, Kondo S, Harano K, Yonemori K, Yoh K, Gu Y, Mita T, Chen X, Ueda E, Yamamoto N, Doi T, Shimizu T. Kuboki Y, et al. Cancer Med. 2024 Apr;13(8):e6980. doi: 10.1002/cam4.6980. Cancer Med. 2024. PMID: 38651187 Free PMC article. Clinical Trial.
BACKGROUND: Retifanlimab is a humanized monoclonal antibody targeting programmed death protein-1, and INCB001158 is an oral arginase inhibitor. ...
BACKGROUND: Retifanlimab is a humanized monoclonal antibody targeting programmed death protein-1, and INCB001158 is an oral arginase …
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.
Curigliano G, Dent R, Earle H, Modi S, Tarantino P, Viale G, Tolaney SM. Curigliano G, et al. ESMO Open. 2024 Apr;9(4):102989. doi: 10.1016/j.esmoop.2024.102989. Epub 2024 Apr 12. ESMO Open. 2024. PMID: 38613914 Free PMC article. Review.
The DESTINY-Breast04 trial established that HER2-low tumors are targetable, leading to the approval of trastuzumab deruxtecan (T-DXd) as the first HER2-directed therapy for the treatment of HER2-low breast cancer in the United States and Europe. This change in the c …
The DESTINY-Breast04 trial established that HER2-low tumors are targetable, leading to the approval of trastuzumab deruxtecan (T-DXd) as the …
Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer.
Franco-Mateos E, Souza-Egipsy V, García-Estévez L, Pérez-García J, Gion M, Garrigós L, Cortez P, Saavedra C, Gómez P, Ortiz C, Cruz VL, Ramos J, Cortés J, Vega JF. Franco-Mateos E, et al. Int J Mol Sci. 2024 Apr 1;25(7):3940. doi: 10.3390/ijms25073940. Int J Mol Sci. 2024. PMID: 38612751 Free PMC article.
The observed increase suggests a potential synergistic effect between these antibodies, which could enhance their therapeutic efficacy in HER2-positive cancers. These findings underscore the importance of understanding the complex interplay between therapeutic antibodie
The observed increase suggests a potential synergistic effect between these antibodies, which could enhance their therapeutic efficac …
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC, Schmidt S, Becker K, Thiele H, Nürnberg P, Richters L, Ernst C, Treilleux I, Medioni J, Heitz F, Pisano C, Garcia Y, Petru E, Hietanen S, Colombo N, Vergote I, Nagao S, Linn SC, Pujade-Lauraine E, Ray-Coquard I, Harter P, Hahnen E, Schmutzler RK. Schouten PC, et al. JAMA Netw Open. 2024 Apr 1;7(4):e245552. doi: 10.1001/jamanetworkopen.2024.5552. JAMA Netw Open. 2024. PMID: 38592722 Free PMC article. Clinical Trial.
IMPORTANCE: Testing for homologous recombination deficiency is required for the optimal treatment of high-grade epithelial ovarian cancer. The search for accurate biomarkers is ongoing. OBJECTIVE: To investigate whether progression-free survival (PFS) and overall survival …
IMPORTANCE: Testing for homologous recombination deficiency is required for the optimal treatment of high-grade epithelial ovarian cancer
Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
Frenel JS, Zeghondy J, Guérin-Charbonnel C, Mailliez A, Volant E, Poumeaud F, Patsouris A, Arnedos M, Bailleux C, Cabal J, Galland L, de Nonneville A, Guiu S, Dalenc F, Pistilli B, Bachelot T, Pierga JY, Le Du F, Bocquet F, Larrouquere L, Loirat D. Frenel JS, et al. JAMA Netw Open. 2024 Apr 1;7(4):e244435. doi: 10.1001/jamanetworkopen.2024.4435. JAMA Netw Open. 2024. PMID: 38568692 Free PMC article.
IMPORTANCE: Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC). OBJECTIVE: To inv …
IMPORTANCE: Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzu …
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak P, Lau C, Meric-Bernstam F. Heist RS, et al. Cancer Treat Rev. 2024 Apr;125:102720. doi: 10.1016/j.ctrv.2024.102720. Epub 2024 Mar 11. Cancer Treat Rev. 2024. PMID: 38502995 Free article. Review.
Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2 (TROP2), a protein that is broadly expressed in several types of solid tumors. ...In the ongoing, first- …
Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a topoisomerase I inhibitor payload and a monoclonal antibody directed to …
A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer.
Zhao L, Chang F, Tong Y, Yin J, Xu J, Li H, Du L, Jiang Y. Zhao L, et al. Adv Sci (Weinh). 2024 Apr;11(16):e2308316. doi: 10.1002/advs.202308316. Epub 2024 Feb 21. Adv Sci (Weinh). 2024. PMID: 38380506 Free PMC article.
Anti-HER2 (human epidermal growth factor receptor 2) therapies significantly increase the overall survival of patients with HER2-positive breast cancer. Unfortunately, a large fraction of patients may develop primary or acquired resistance. ...NIR laser application …
Anti-HER2 (human epidermal growth factor receptor 2) therapies significantly increase the overall survival of patients with HER2-positive …
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
Pourjamal N, Yazdi N, Halme A, Joncour VL, Laakkonen P, Saharinen P, Joensuu H, Barok M. Pourjamal N, et al. Clin Exp Metastasis. 2024 Apr;41(2):91-102. doi: 10.1007/s10585-024-10278-2. Epub 2024 Feb 17. Clin Exp Metastasis. 2024. PMID: 38367127 Free PMC article.
Human epidermal growth factor 2 (HER2)-positive breast cancer with lung metastases resistant to targeted agents is a common therapeutic challenge. ...In a mouse model, all three ADCs inhibited the growth of L-JIMT-1 lung metastases compared to a vehicle, but DV and …
Human epidermal growth factor 2 (HER2)-positive breast cancer with lung metastases resistant to targeted agents is a common th …
Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
Wyrwicz L, Rodríguez Sánchez CA, Sánchez-Rovira P, Lewis S, Sandschafer D, San T. Wyrwicz L, et al. Future Oncol. 2024 Apr;20(13):821-832. doi: 10.2217/fon-2023-0421. Epub 2024 Feb 2. Future Oncol. 2024. PMID: 38305004 Free article.
Conclusion: Trastuzumab-anns was widely used in various treatment settings for HER2+ breast cancer. Some patients have a type of breast cancer caused by abnormal amounts of a normal growth factor receptor. ...HER2+ breast cancer can be tr …
Conclusion: Trastuzumab-anns was widely used in various treatment settings for HER2+ breast cancer. Some patients have a type …
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
Tan TJ, Sammons S, Im YH, She L, Mundy K, Bigelow R, Traina TA, Anders C, Yeong J, Renzulli E, Kim SB, Dent R. Tan TJ, et al. Clin Cancer Res. 2024 Apr 1;30(7):1240-1247. doi: 10.1158/1078-0432.CCR-23-2513. Clin Cancer Res. 2024. PMID: 38236575 Free PMC article. Clinical Trial.
PURPOSE: We explored the efficacy of PARP inhibition with or without programmed death ligand-1 (PD-L1) blockade as chemotherapy-free maintenance therapy for advanced triple-negative breast cancer (aTNBC) sensitive to platinum-based chemotherapy. PATIENTS AND METHODS …
PURPOSE: We explored the efficacy of PARP inhibition with or without programmed death ligand-1 (PD-L1) blockade as chemotherapy-free mainten …
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.
Zhu Y, Zerdes I, Matikas A, Cruz IR, Bergqvist M, Elinder E, Bosch A, Lindman H, Einbeigi Z, Andersson A, Carlsson L, Dreifaldt AC, Isaksson-Friman E, Hellstrom M, Johansson H, Wang K, Bergh JCS, Hatschek T, Foukakis T. Zhu Y, et al. Breast Cancer Res Treat. 2024 Apr;204(2):299-308. doi: 10.1007/s10549-023-07200-x. Epub 2024 Jan 4. Breast Cancer Res Treat. 2024. PMID: 38175448 Free PMC article. Clinical Trial.
TK1 has been studied as a prognostic marker and as an early indicator of treatment response in human epidermal growth factor 2 (HER2)-negative early and metastatic breast cancer (BC). However, the prognostic and predictive value of serial TK1 activity in HER2-positi …
TK1 has been studied as a prognostic marker and as an early indicator of treatment response in human epidermal growth factor 2 (HER2)-negati …
Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study.
Jiang K, Hong R, Xia W, Lu Q, Li L, Huang J, Shi Y, Yuan Z, Zheng Q, An X, Xue C, Huang J, Bi X, Chen M, Zhang J, Xu F, Wang S. Jiang K, et al. Cancer Res Treat. 2024 Apr;56(2):513-521. doi: 10.4143/crt.2023.786. Epub 2023 Oct 12. Cancer Res Treat. 2024. PMID: 37846468 Free PMC article.
PURPOSE: This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and provide higher level evidence for clinical practic …
PURPOSE: This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal …
The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.
Park M, Jung E, Park JM, Park S, Ko D, Seo J, Kim S, Nam KD, Kang YK, Farrand L, Hoang VH, Nguyen CT, La MT, Nam G, Park HJ, Ann J, Lee J, Kim YJ, Kim JY, Seo JH. Park M, et al. Theranostics. 2024 Mar 31;14(6):2442-2463. doi: 10.7150/thno.93236. eCollection 2024. Theranostics. 2024. PMID: 38646654 Free PMC article.
Rationale: Resistance to targeted therapies like trastuzumab remains a critical challenge for HER2-positive breast cancer patients. Despite the progress of several N-terminal HSP90 inhibitors in clinical trials, none have achieved approval for clinical use, primaril …
Rationale: Resistance to targeted therapies like trastuzumab remains a critical challenge for HER2-positive breast cancer pati …
Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice.
Bonomi M, Spada D, Baiocchi GL, Celotti A, Brighenti M, Grizzi G. Bonomi M, et al. Int J Mol Sci. 2024 Mar 30;25(7):3876. doi: 10.3390/ijms25073876. Int J Mol Sci. 2024. PMID: 38612688 Free PMC article. Review.
Gastroesophageal adenocarcinoma (GEA) is one of the principal causes of death related to cancer globally. Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor which is found to be overexpressed or amplified in approximately 20% of GEA cases. ...The …
Gastroesophageal adenocarcinoma (GEA) is one of the principal causes of death related to cancer globally. Human epidermal growth fact …
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x. Nat Commun. 2024. PMID: 38538574 Free PMC article. Clinical Trial.
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immuno …
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast
Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports.
Yanase Y, Bando H, Sato R, Matsuo T, Ueda A, Okazaki M, Hashimoto S, Iguchi-Manaka A, Hara H. Yanase Y, et al. J Med Case Rep. 2024 Mar 25;18(1):150. doi: 10.1186/s13256-024-04478-3. J Med Case Rep. 2024. PMID: 38523303 Free PMC article.
CASE REPORT: We report two cases of recurrent severe hypocalcemia occurring during chemotherapy for metastatic breast cancer with multiple bone metastases. Case 1: A 35-year-old Japanese woman developed metastases in the bone, liver, and ovaries during postoperative …
CASE REPORT: We report two cases of recurrent severe hypocalcemia occurring during chemotherapy for metastatic breast cancer w …
Xianling Lianxia formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer.
Li F, Wu Y, Shi Y, Liu X, Xie Y, Liu S. Li F, et al. Acta Biochim Biophys Sin (Shanghai). 2024 Mar 25;56(3):462-473. doi: 10.3724/abbs.2023281. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38379418 Free article.
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is characterized by high invasiveness. Trastuzumab considerably improves the prognoses of HER2-positive BC, but some patients exhibit drug resistance. ...
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is characterized by high invasiveness. Trastuzumab …
Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer.
Muñoz C, Tai X, Arias J, Eisen A, Chaudhry M, Gavura S, Chan KKW. Muñoz C, et al. Curr Oncol. 2024 Mar 21;31(3):1633-1644. doi: 10.3390/curroncol31030124. Curr Oncol. 2024. PMID: 38534957 Free PMC article.
Background: Ontario publicly funds reference trastuzumab (Herceptin) and four biosimilar trastuzumab products for adjuvant treatment of HER2+ breast cancer. We assessed the real-world safety and effectiveness of biosimilar trastuzumab compared to Herceptin for adjuv …
Background: Ontario publicly funds reference trastuzumab (Herceptin) and four biosimilar trastuzumab products for adjuvant treatment of HER2 …
Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy.
Pang J, Ding N, Yin N, Xiao Z. Pang J, et al. Sci Rep. 2024 Mar 19;14(1):6578. doi: 10.1038/s41598-024-57343-0. Sci Rep. 2024. PMID: 38503890 Free PMC article.
The prognostic value of SII (Systemic Immune-Inflammation Index) in HER-2-positive breast cancer (BC) patients, regardless of whether they receive trastuzumab treatment, and its potential value to distinguish patients who may benefit from trastuzumab therapy, warran …
The prognostic value of SII (Systemic Immune-Inflammation Index) in HER-2-positive breast cancer (BC) patients, regardless of …
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer.
Garber HR, Basu S, Jindal S, He Z, Chu K, Raghavendra AS, Yam C, Santiago L, Adrada BE, Sharma P, Mittendorf EA, Litton JK. Garber HR, et al. Oncotarget. 2024 Mar 19;15:238-247. doi: 10.18632/oncotarget.28567. Oncotarget. 2024. PMID: 38502947 Free PMC article.
A clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (N …
A clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-neg …
Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC.
Nagy L, Mezősi-Csaplár M, Rebenku I, Vereb G, Szöőr Á. Nagy L, et al. Front Immunol. 2024 Mar 18;15:1365172. doi: 10.3389/fimmu.2024.1365172. eCollection 2024. Front Immunol. 2024. PMID: 38562932 Free PMC article.
Universal CAR T cells (UniCAR Ts) provide a promising solution by utilizing molecular tags (linkers), such as biotin conjugated to monoclonal antibodies, enabling them to target a variety of tumor antigens. Recently, we showed that conventional CAR T cells could pen …
Universal CAR T cells (UniCAR Ts) provide a promising solution by utilizing molecular tags (linkers), such as biotin conjugated to monocl
Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice.
Khoshtinat Nikkhoi S, Yang G, Owji H, Grizotte-Lake M, Cohen RI, Gil Gonzalez L, Massumi M, Hatefi A. Khoshtinat Nikkhoi S, et al. J Immunother Cancer. 2024 Mar 15;12(3):e008295. doi: 10.1136/jitc-2023-008295. J Immunother Cancer. 2024. PMID: 38490714 Free PMC article.
The BiKE:E5C1 exhibits high affinity/specificity for the CD16a activating receptor on natural killer (NK) cells and human epidermal growth factor receptor 2 (HER2) on cancer cells. In vitro studies have demonstrated that BiKE:E5C1 can activate the NK cells and induce the k …
The BiKE:E5C1 exhibits high affinity/specificity for the CD16a activating receptor on natural killer (NK) cells and human epidermal growth f …
Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam.
Nguyen AQ, Tran OTM, Nguyen PK, Nguyen HT. Nguyen AQ, et al. PLoS One. 2024 Mar 15;19(3):e0300474. doi: 10.1371/journal.pone.0300474. eCollection 2024. PLoS One. 2024. PMID: 38489305 Free PMC article.
The research aims to evaluate the cost-effectiveness of one-year adjuvant trastuzumab therapy for early-stage breast cancer patients with human epidermal growth receptor 2 (HER2+) from a societal perspective. ...CONCLUSION: In Vietnam, one-year adjuvant trastuzumab …
The research aims to evaluate the cost-effectiveness of one-year adjuvant trastuzumab therapy for early-stage breast cancer pa …
A Cell-Penetrating Peptide Improves Anti-HER2 Single-Chain Variable Fragment Internalization and Antitumor Activity against HER2-Positive Breast Cancer In Vitro and In Vivo.
Li J, Zhou Y, Su Z, Li X, Zhang L, Li S. Li J, et al. Molecules. 2024 Mar 11;29(6):1247. doi: 10.3390/molecules29061247. Molecules. 2024. PMID: 38542884 Free PMC article.
Both the single-chain antibodies and LP-scFv reduced the viability of BT474 and NCI-N87 cells in a dose-dependent manner while exhibiting minimal toxicity towards MCF-7 and MCF-10A cells. ...This research lays the foundation for designing novel antibody-based therapies for …
Both the single-chain antibodies and LP-scFv reduced the viability of BT474 and NCI-N87 cells in a dose-dependent manner while exhibi …
Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.
Mäenpää N, Tiainen L, Hämäläinen M, Luukkaala T, Tanner M, Lahdenperä O, Vihinen P, Karihtala P, Kellokumpu-Lehtinen PL, Moilanen E, Jukkola A. Mäenpää N, et al. BMC Cancer. 2024 Mar 11;24(1):331. doi: 10.1186/s12885-024-12070-7. BMC Cancer. 2024. PMID: 38468231 Free PMC article.
The objective of this study was to investigate the prognostic value of the VEGF family in patients treated for metastatic breast cancer. The emphasis was on neuropilin-1 (NRP-1) and placental growth factor (PlGF). ...CONCLUSION: Especially NRP-1 and PlGF have progno …
The objective of this study was to investigate the prognostic value of the VEGF family in patients treated for metastatic breast c
Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial.
Huang L, Pang D, Yang H, Li W, Wang S, Cui S, Liao N, Wang Y, Wang C, Chang YC, Wang HC, Kang SY, Seo JH, Shen K, Laohawiriyakamol S, Jiang Z, Wang H, Lamour F, Song G, Curran M, Duan C, Lysbet de Haas S, Restuccia E, Shao Z. Huang L, et al. Nat Commun. 2024 Mar 9;15(1):2153. doi: 10.1038/s41467-024-45591-7. Nat Commun. 2024. PMID: 38461323 Free PMC article. Clinical Trial.
The randomized, multicenter, double-blind, placebo-controlled, phase III PEONY trial (NCT02586025) demonstrated significantly improved total pathologic complete response (primary endpoint) with dual HER2 blockade in HER2-positive early/locally advanced breast cancer
The randomized, multicenter, double-blind, placebo-controlled, phase III PEONY trial (NCT02586025) demonstrated significantly improved total …
Evidence for cytoprotective autophagy in response to HER2-targeted monoclonal antibodies.
Elshazly AM, Elzahed AA, Gewirtz DA. Elshazly AM, et al. J Pharmacol Exp Ther. 2024 Mar 7:JPET-MR-2023-002048. doi: 10.1124/jpet.123.002048. Online ahead of print. J Pharmacol Exp Ther. 2024. PMID: 38453523 Free article.
The advent of HER2-targeted monoclonal antibodies such as trastuzumab has significantly improved the clinical outcomes for patients with breast cancer overexpressing HER2, and more recently also for gastric cancers. ...In this review, we provide an ove …
The advent of HER2-targeted monoclonal antibodies such as trastuzumab has significantly improved the clinical outcomes for pat …
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Jañez NM, Trigo J, Greystoke A, Harvey RD, Olszanski AJ, Opyrchal M, Spira A, Thistlethwaite F, Jiménez B, Sappal JH, Kannan K, Riley J, Li C, Li C, Gregory RC, Miao H, Wang S. Juric D, et al. Cancer Med. 2024 Mar;13(5):10.1002/cam4.6776. doi: 10.1002/cam4.6776. Cancer Med. 2024. PMID: 38501219 Free PMC article. Clinical Trial.
Mivavotinib (TAK-659/CB-659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti-PD-1 therapy in cancer models. This dose-escalation/expansion study investigated the safety, pharmacokinetics, ph …
Mivavotinib (TAK-659/CB-659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in co …
Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India.
Wadhwa R, Gupta N, Dixit J, Malhotra P, Lakshmi P, Prinja S. Wadhwa R, et al. JCO Glob Oncol. 2024 Mar;10:e2300396. doi: 10.1200/GO.23.00396. JCO Glob Oncol. 2024. PMID: 38452304 Free PMC article.
RESULTS: Over a lifetime, the incremental number of SREs averted with use of denosumab once every 4 weeks (compared with ZA once every 4 weeks and once every 12 weeks) among patients with luminal A, luminal B, human epidermal growth factor receptor 2-enriched, and triple negative …
RESULTS: Over a lifetime, the incremental number of SREs averted with use of denosumab once every 4 weeks (compared with ZA once every 4 wee …
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B).
Villacampa G, Pascual T, Brasó-Maristany F, Paré L, Martínez-Sáez O, Cortés J, Ciruelos E, Martin M, Conte P, Carey LA, Fernandez A, Harbeck N, Marín-Aguilera M, Vivancos A, Curigliano G, Villagrasa P, Parker JS, Perou CM, Prat A, Tolaney SM. Villacampa G, et al. ESMO Open. 2024 Mar;9(3):102388. doi: 10.1016/j.esmoop.2024.102388. Epub 2024 Mar 4. ESMO Open. 2024. PMID: 38442452 Free PMC article.
BACKGROUND: The HER2DX risk-score has undergone rigorous validation in prior investigations involving patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer. In this study, we present the outcomes of the HER2DX risk- …
BACKGROUND: The HER2DX risk-score has undergone rigorous validation in prior investigations involving patients with early-stage human epider …
Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.
Blas PE, Rodriguez ESR, Williams HL, Levin MK, Bell JSK, Pierobon M, Barrett AS, Petricoin EF, O'Shaughnessy JA. Blas PE, et al. Cancer Rep (Hoboken). 2024 Mar;7(3):e1954. doi: 10.1002/cnr2.1954. Cancer Rep (Hoboken). 2024. PMID: 38441358 Free PMC article.
BACKGROUND: Overexpression of HER2 plays an important role in cancer progression and is the target of multiple therapies in HER2-positive breast cancer. ...METHODS: In this report, we present two exceptional responses in hormone receptor-positive, HER2-nonamp …
BACKGROUND: Overexpression of HER2 plays an important role in cancer progression and is the target of multiple therapies in HER2-posi …
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects.
Fusco V, Di Maio M, Valsecchi AA, Santini D, Tucci M, De Giorgi U, Bossi P, Ibrahim T, Cavanna L, Lanzetta G, Rossi M, Rossetti G, Airoldi M, Comandone A, Cinieri S. Fusco V, et al. Support Care Cancer. 2024 Mar 1;32(3):202. doi: 10.1007/s00520-024-08392-8. Support Care Cancer. 2024. PMID: 38427111 Free PMC article.
METHODS: Italian oncologists were invited to fulfil a 24-question web survey about prescription of BMAs for bone metastases of breast cancer, prostate cancer, and other solid tumors. Prevention and management of side effects were also investigated. ...BMAs ar …
METHODS: Italian oncologists were invited to fulfil a 24-question web survey about prescription of BMAs for bone metastases of breast
Small molecule agents for triple negative breast cancer: Current status and future prospects.
Ou Y, Wang M, Xu Q, Sun B, Jia Y. Ou Y, et al. Transl Oncol. 2024 Mar;41:101893. doi: 10.1016/j.tranon.2024.101893. Epub 2024 Jan 29. Transl Oncol. 2024. PMID: 38290250 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis. ...Although monoclonal antibodies have produced clinical success, their large molecular weight can limit therapeutic benefits. ...
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis. ...Although monoclona
First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
Yeh R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park S, Brockway JP, Bromberg JF, Zhi WI, Robson ME, Sanford R, Modi S, Agnew BJ, Lyashchenko SK, Lewis JS, Ulaner GA, Zeglis BM. Yeh R, et al. J Nucl Med. 2024 Mar 1;65(3):386-393. doi: 10.2967/jnumed.123.266392. J Nucl Med. 2024. PMID: 38272704 Free PMC article.
Here, we describe a first-in-human PET study on patients with HER2-positive breast cancer evaluating the safety, biodistribution, and dosimetry of (89)Zr-site-specific (ss)-pertuzumab PET, a site-specifically labeled radioimmunoconjugate designed to circumvent the l …
Here, we describe a first-in-human PET study on patients with HER2-positive breast cancer evaluating the safety, biodistributi …
Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.
Ten Haaft BH, Pedregal M, Prato J, Klümpen HJ, Moreno V, Lamarca A. Ten Haaft BH, et al. Eur J Cancer. 2024 Mar;199:113564. doi: 10.1016/j.ejca.2024.113564. Epub 2024 Jan 20. Eur J Cancer. 2024. PMID: 38266541 Free article. Review.
Biliary tract cancers (BTCs) encompass a heterogeneous group of rare tumors, including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer (GBC) and ampullary cancer (AC). The present first-line palliative treatment reg …
Biliary tract cancers (BTCs) encompass a heterogeneous group of rare tumors, including intrahepatic cholangiocarcinoma (iCCA), extrahepatic …
Implication of IZUMO2 in the cell-in-cell phenomenon: A potential therapeutic target for triple-negative breast cancer.
Higashi T, Saigo C, Chikaishi W, Hayashi H, Hanamatsu Y, Futamura M, Matsuhashi N, Takeuchi T. Higashi T, et al. Thorac Cancer. 2024 Mar;15(7):513-518. doi: 10.1111/1759-7714.15189. Epub 2024 Jan 23. Thorac Cancer. 2024. PMID: 38258402 Free PMC article.
BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by the loss of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. ...In this study, we aimed to elucidate the molecule that allows TNBC cells to engulf A-Tregs. ME …
BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by the loss of estrogen receptor, progesterone receptor, and …
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer.
Zou H, Luo J, Guo Y, Deng L, Zeng L, Pan Y, Li P. Zou H, et al. Drug Resist Updat. 2024 Mar;73:101051. doi: 10.1016/j.drup.2024.101051. Epub 2024 Jan 9. Drug Resist Updat. 2024. PMID: 38219531 Free article.
Trastuzumab resistance in HER2+ breast cancer (BC) is the major reason leading to poor prognosis of BC patients. ...
Trastuzumab resistance in HER2+ breast cancer (BC) is the major reason leading to poor prognosis of BC patients. ...
Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study.
Zheng C, Liu Y, Wang X, Bi Z, Qiu P, Qiao G, Bi X, Shi Z, Zhang Z, Chen P, Sun X, Wang C, Zhu S, Meng X, Song Y, Qi Y, Li L, Luo N, Wang Y. Zheng C, et al. Int J Surg. 2024 Mar 1;110(3):1527-1536. doi: 10.1097/JS9.0000000000001011. Int J Surg. 2024. PMID: 38116673 Free PMC article. Clinical Trial.
BACKGROUND: Triple-negative breast cancer (TNBC) is associated with a dismal prognosis. Immune checkpoint inhibitors have shown promising antitumor activity in neoadjuvant settings. ...The primary endpoint was total pathological complete response (pCR). Secondary en …
BACKGROUND: Triple-negative breast cancer (TNBC) is associated with a dismal prognosis. Immune checkpoint inhibitors have show …
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
Saura C, Modi S, Krop I, Park YH, Kim SB, Tamura K, Iwata H, Tsurutani J, Sohn J, Mathias E, Liu Y, Cathcart J, Singh J, Yamashita T. Saura C, et al. Ann Oncol. 2024 Mar;35(3):302-307. doi: 10.1016/j.annonc.2023.12.001. Epub 2023 Dec 11. Ann Oncol. 2024. PMID: 38092229 Free article. Clinical Trial.
BACKGROUND: Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-pos …
BACKGROUND: Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-Breast01 trial (median follow-up 11.1 months) demo …
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. Bardia A, et al. Future Oncol. 2024 Mar;20(8):423-436. doi: 10.2217/fon-2023-0188. Epub 2023 Jun 30. Future Oncol. 2024. PMID: 37387213 Free article.
Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. ...At …
Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that …
CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts.
Alotaibi FM, Min WP, Koropatnick J. Alotaibi FM, et al. Front Immunol. 2024 Feb 29;15:1256766. doi: 10.3389/fimmu.2024.1256766. eCollection 2024. Front Immunol. 2024. PMID: 38487537 Free PMC article.
Blocking CD5 function may have therapeutic potential in treatment of cancer by enhancing cytotoxic T lymphocyte recognition and ablation of tumour cells. The effect of administering an anti-CD5 antibody to block or reduce CD5 function as an immune checkpoint blockade to en …
Blocking CD5 function may have therapeutic potential in treatment of cancer by enhancing cytotoxic T lymphocyte recognition and ablat …
Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads.
Monteiro MR, Nunes NCC, Junior AADS, Fêde ABS, Bretas GO, Souza CP, Mano M, da Silva JL. Monteiro MR, et al. Breast Cancer (Dove Med Press). 2024 Feb 28;16:51-70. doi: 10.2147/BCTT.S448191. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 38434801 Free PMC article. Review.
Antibody-drug conjugates (ADCs) have surfaced as a promising group of anticancer agents employing the precise targeting capacity of monoclonal antibodies to transport highly effective cytotoxic payloads. ...This thorough review provides an in-depth analysis of the c …
Antibody-drug conjugates (ADCs) have surfaced as a promising group of anticancer agents employing the precise targeting capacity of monoc
(177)Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer.
Salvanou EA, Kolokithas-Ntoukas A, Prokopiou D, Theodosiou M, Efthimiadou E, Koźmiński P, Xanthopoulos S, Avgoustakis K, Bouziotis P. Salvanou EA, et al. Molecules. 2024 Feb 27;29(5):1030. doi: 10.3390/molecules29051030. Molecules. 2024. PMID: 38474542 Free PMC article.
The aim of our current study was to evaluate the potential of iron oxide nanoparticles, coated with alginic acid and polyethylene glycol, functionalized with the chemotherapeutic agent doxorubicin and the monoclonal antibody bevacizumab, to serve as a nanoradiopharmaceutic …
The aim of our current study was to evaluate the potential of iron oxide nanoparticles, coated with alginic acid and polyethylene glycol, fu …
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
Eitler J, Rackwitz W, Wotschel N, Gudipati V, Murali Shankar N, Sidorenkova A, Huppa JB, Ortiz-Montero P, Opitz C, Künzel SR, Michen S, Temme A, Loureiro LR, Feldmann A, Bachmann M, Boissel L, Klingemann H, Wels WS, Tonn T. Eitler J, et al. J Immunother Cancer. 2024 Feb 27;12(2):e008155. doi: 10.1136/jitc-2023-008155. J Immunother Cancer. 2024. PMID: 38417916 Free PMC article.
RESULTS: Blockade of LFA-1 or absence of ICAM-1 significantly reduced cell killing and cytokine release during trastuzumab-mediated ADCC against ErbB2-positive breast cancer cells, but not so in CAR-targeted NK cells. Pretreatment with 5-aza-2'-deoxycytidine induced …
RESULTS: Blockade of LFA-1 or absence of ICAM-1 significantly reduced cell killing and cytokine release during trastuzumab-mediated ADCC aga …
Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors.
Xu C, Wang Q, Wang D, Wang W, Fang W, Li Z, Liu A, Yu J, Zhong W, Wang Z, Zhang Y, Liu J, Zhang S, Cai X, Liu A, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Chen Y, Yuan J, Wang F, Jiang Z, Lin G, Huang L, Pu X, Lin R, Liu W, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Xue J, Guo H, Chu Q, Meng R, Wu J, Zhang R, Zhou J, Zhu Z, Li Y, Qiu H, Xia F, Lu Y, Chen X, Ge R, Dai E, Han Y, Pan W, Pang F, He Q, Huang J, Wang K, Wu F, Xu B, Wang L, Zhu Y, Lin L, Xie Y, Lin X, Cai J, Xu L, Li J, Jiao X, Li K, Wei J, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Feng Y, Zhang Y, Sun P, Wang H, Ye M, Wang Z, Hao Y, Wang Z, Wan B, Lv D, Yang S, Kang J, Zhang J, Zhang C, Ou J, Shi L, Wang Y, Li B, Zhang Z, Li Z, Liu Z, Yang N, Wu L, Wang H, Jin G, Wang G, Wang J, Fang M, Fang Y, Li Y, Wang X, Zhang Y, Zhu X, Shen Y, Ma S, Wang B, Si L, Song Y, Lu Y, Chen J, Song Z. Xu C, et al. Glob Med Genet. 2024 Feb 27;11(1):86-99. doi: 10.1055/s-0044-1781457. eCollection 2024 Jan. Glob Med Genet. 2024. PMID: 38414979 Free PMC article. Review.
The incidence of NRG1 gene fusion varies across cancer types, with lung cancer being the most prevalent at 0.19 to 0.27%. ...Common treatment approaches involve pan-ERBB inhibitors, small molecule inhibitors targeting ERBB2 or ERBB3, and monoclonal antibod
The incidence of NRG1 gene fusion varies across cancer types, with lung cancer being the most prevalent at 0.19 to 0.27%. ...C …
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Shatsky RA, Batra-Sharma H, Helsten T, Schwab RB, Pittman EI, Pu M, Weihe E, Ghia EM, Rassenti LZ, Molinolo A, Cabrera B, Breitmeyer JB, Widhopf GF 2nd, Messer K, Jamieson C, Kipps TJ, Parker BA. Shatsky RA, et al. Breast Cancer Res. 2024 Feb 26;26(1):32. doi: 10.1186/s13058-024-01782-0. Breast Cancer Res. 2024. PMID: 38408999 Free PMC article. Clinical Trial.
BACKGROUND: Zilovertamab is a humanized monoclonal antibody targeting ROR1, an onco-embryonic antigen expressed by malignant cells of a variety of solid tumors, including breast cancer. ...CONCLUSION: The combination of zilovertamab and paclitaxel was safe an …
BACKGROUND: Zilovertamab is a humanized monoclonal antibody targeting ROR1, an onco-embryonic antigen expressed by malignant cells of …
Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options.
Premji SK, O'Sullivan CC. Premji SK, et al. Breast Cancer (Auckl). 2024 Feb 25;18:11782234241234418. doi: 10.1177/11782234241234418. eCollection 2024. Breast Cancer (Auckl). 2024. PMID: 38410761 Free PMC article. Review.
Prior to the advent of the HER2-targeted monoclonal antibody trastuzumab, HER2+ breast cancer (BC) was considered an aggressive disease with a poor prognosis. ...Of particular interest are established and novel antibody-drug conjugates, as well as other novel …
Prior to the advent of the HER2-targeted monoclonal antibody trastuzumab, HER2+ breast cancer (BC) was considered an ag …
Primary thyroid lymphoma: a case series.
Sakhri S, Zemni I, Ayadi MA, Kamoun S, Chargui R, Ben Dhiab T. Sakhri S, et al. J Med Case Rep. 2024 Feb 24;18(1):108. doi: 10.1186/s13256-024-04434-1. J Med Case Rep. 2024. PMID: 38395921 Free PMC article.
It is a rare disease accounting for around 5% of the thyroid neoplasms and 2% of extranodal lymphomas. If properly diagnosed and treated, the prognosis is favorable. ...The mean age was 76.2 (range: 63-95 years); one patient had associated hypothyroid. One patient had a me …
It is a rare disease accounting for around 5% of the thyroid neoplasms and 2% of extranodal lymphomas. If properly diagnosed and trea …
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
Cardillo TM, Zalath MB, Arrojo R, Sharkey RM, Govindan SV, Chang CH, Goldenberg DM. Cardillo TM, et al. Oncotarget. 2024 Feb 22;15:144-158. doi: 10.18632/oncotarget.28559. Oncotarget. 2024. PMID: 38386805 Free PMC article.
SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (TNBC), unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative …
SG has received United States Food and Drug Administration (FDA) approval to treat metastatic triple-negative breast cancer (T …
Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial.
Zhang M, Zhang G, Niu Y, Zhang G, Ji Y, Yan X, Zhang X, Wang Q, Jing X, Wang J, Ma Z, Wang H. Zhang M, et al. Nat Commun. 2024 Feb 19;15(1):1512. doi: 10.1038/s41467-024-45769-z. Nat Commun. 2024. PMID: 38374204 Free PMC article. Clinical Trial.
This was a single-arm, multicenter phase 2 clinical trial (ChiCTR1900021726) involving advanced squamous non-small cell lung cancer (sq-NSCLC) patients undergoing 2 cycles of nab-paclitaxel/carboplatin and sintilimab (anti-PD-1), followed by sintilimab maintenance therapy. …
This was a single-arm, multicenter phase 2 clinical trial (ChiCTR1900021726) involving advanced squamous non-small cell lung cancer ( …
The unique monoclonal antibodies and immunochemical assay for comprehensive determination of the cell-bound and soluble HER2 in different biological samples.
Antos A, Topolska-Woś A, Woś M, Mitura A, Sarzyńska P, Lipiński T, Kurylcio A, Ziółkowski P, Świtalska M, Tkaczuk-Włach J, Gamian A, Polkowski WP, Staniszewska M. Antos A, et al. Sci Rep. 2024 Feb 17;14(1):3978. doi: 10.1038/s41598-024-54590-z. Sci Rep. 2024. PMID: 38368450 Free PMC article.
The expression of the HER2 (human epidermal growth factor receptor 2) protein in cancer cells is a well-established cancer marker used for diagnostic and therapeutic purposes in modern treatment protocols, especially in breast cancer. ...There is a nee …
The expression of the HER2 (human epidermal growth factor receptor 2) protein in cancer cells is a well-established cancer mar …
Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
Zimmerman BS, Esteva FJ. Zimmerman BS, et al. Cancers (Basel). 2024 Feb 16;16(4):800. doi: 10.3390/cancers16040800. Cancers (Basel). 2024. PMID: 38398191 Free PMC article. Review.
Patients have traditionally been treated with a combination of chemotherapy and HER2-targeted monoclonal antibodies such as trastuzumab and pertuzumab. The HER2-targeted antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) …
Patients have traditionally been treated with a combination of chemotherapy and HER2-targeted monoclonal antibodies such as tr …
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Hieken TJ, et al. Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8. Nat Commun. 2024. PMID: 38365756 Free PMC article. Clinical Trial.
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.
Schmid P, Turner NC, Barrios CH, Isakoff SJ, Kim SB, Sablin MP, Saji S, Savas P, Vidal GA, Oliveira M, O'Shaughnessy J, Italiano A, Espinosa E, Boni V, White S, Rojas B, Freitas-Junior R, Chae Y, Bondarenko I, Lee J, Torres Mattos C, Martinez Rodriguez JL, Lam LH, Jones S, Reilly SJ, Huang X, Shah K, Dent R. Schmid P, et al. Clin Cancer Res. 2024 Feb 16;30(4):767-778. doi: 10.1158/1078-0432.CCR-23-2084. Clin Cancer Res. 2024. PMID: 38060199 Free PMC article. Clinical Trial.
PURPOSE: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC). PATIENTS AND METHODS: The single-arm CO40151 phase …
PURPOSE: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line the …
Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study.
Li C, Sun L, Liu Z, Sun H, Wang X, Yu Q, Yu Z. Li C, et al. Am J Cancer Res. 2024 Feb 15;14(2):869-879. doi: 10.62347/EMIK7909. eCollection 2024. Am J Cancer Res. 2024. PMID: 38455400 Free PMC article.
Disitamab vedotin (RC48) is a novel cleavable antibody-drug conjugate (ADC) that has shown promising preclinical activity in HER2-positive breast cancer. However, real-world data regarding its efficacy and safety is lacking, especially in patients previously treated …
Disitamab vedotin (RC48) is a novel cleavable antibody-drug conjugate (ADC) that has shown promising preclinical activity in HER2-positive …
Scoparone attenuates PD-L1 expression in human breast cancer cells by MKP-3 upregulation.
Kim SW, Kim CW, Kim HS. Kim SW, et al. Anim Cells Syst (Seoul). 2024 Feb 9;28(1):55-65. doi: 10.1080/19768354.2024.2315950. eCollection 2024. Anim Cells Syst (Seoul). 2024. PMID: 38348341 Free PMC article.
Breast cancer is a frequently occurring malignant tumor that is one of the leading causes of cancer-related deaths in women worldwide. Monoclonal antibodies that block programed cell death 1 (PD-1)/programed cell death ligand 1 (PD-L1) - a typic
Breast cancer is a frequently occurring malignant tumor that is one of the leading causes of cancer-related deaths in w
Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients.
Song Y, Geng QC, An WJ, Zhang FC, Jiang R, Zhao RS, Deng ZJ, Li H. Song Y, et al. Mol Cell Oncol. 2024 Feb 7;11(1):2309715. doi: 10.1080/23723556.2024.2309715. eCollection 2024. Mol Cell Oncol. 2024. PMID: 38343433 Free PMC article.
Breast cancer was considered as a kind of prone breast tumors with the complicated pathological mechanisms and diverse clinical classifications. In the clinical treatments of HER2-positive tumor patients, HER2 monoclonal antibodies, such as Herc
Breast cancer was considered as a kind of prone breast tumors with the complicated pathological mechanisms and diverse
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.
Rönnlund C, Sifakis EG, Schagerholm C, Yang Q, Karlsson E, Chen X, Foukakis T, Weidler J, Bates M, Fredriksson I, Robertson S, Hartman J. Rönnlund C, et al. Breast Cancer Res. 2024 Feb 7;26(1):24. doi: 10.1186/s13058-024-01779-9. Breast Cancer Res. 2024. PMID: 38321542 Free PMC article.
BACKGROUND: Overexpression of human epidermal growth factor receptor 2 (HER2) caused by HER2 gene amplification is a driver in breast cancer tumorigenesis. We aimed to investigate the prognostic significance of manual scoring and digital image analysis (DIA) algorit …
BACKGROUND: Overexpression of human epidermal growth factor receptor 2 (HER2) caused by HER2 gene amplification is a driver in breast
A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models.
Kaneko MK, Suzuki H, Ohishi T, Nakamura T, Tanaka T, Kato Y. Kaneko MK, et al. Int J Mol Sci. 2024 Feb 5;25(3):1941. doi: 10.3390/ijms25031941. Int J Mol Sci. 2024. PMID: 38339219 Free PMC article.
In this study, we showed that H(2)Mab-250 reacted with HER2-positive breast cancer cells but did not show reactivity to normal epithelial cells in flow cytometry. ...H(2)Mab-250 could contribute to the development of chimeric antigen receptor-T or antibody-drug conj …
In this study, we showed that H(2)Mab-250 reacted with HER2-positive breast cancer cells but did not show reactivity to normal …
Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer.
Sha R, Dong X, Yan S, Dai H, Sun A, You L, Guo Z. Sha R, et al. Sci Rep. 2024 Feb 5;14(1):2908. doi: 10.1038/s41598-024-52638-8. Sci Rep. 2024. PMID: 38316885 Free PMC article.
Breast cancer is the most common diagnosed cancer, the HER2-positive subtype account for 15% of all breast cancer. ...However, the roles of cuproptosis-related genes in HER2-positive breast cancer remain largely unknown. In the pre
Breast cancer is the most common diagnosed cancer, the HER2-positive subtype account for 15% of all breast ca
HER2-targeted therapies in cancer: a systematic review.
Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. Zhu K, et al. Biomark Res. 2024 Feb 2;12(1):16. doi: 10.1186/s40364-024-00565-1. Biomark Res. 2024. PMID: 38308374 Free PMC article. Review.
An increasing number of HER2-targeted drugs including specific monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs) have been approved by the U.S. ...The emergence of ADCs, has significantly transformed the treatment landscap …
An increasing number of HER2-targeted drugs including specific monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and a …
High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.
Furuya K, Nakajima M, Tsunedomi R, Nakagami Y, Xu M, Matsui H, Tokumitsu Y, Shindo Y, Watanabe Y, Tomochika S, Maeda N, Iida M, Suzuki N, Takeda S, Hazama S, Ioka T, Hoshii Y, Ueno T, Nagano H. Furuya K, et al. BMC Cancer. 2024 Feb 2;24(1):165. doi: 10.1186/s12885-024-11924-4. BMC Cancer. 2024. PMID: 38308214 Free PMC article.
BACKGROUND: To improve the prognosis of patients with metastatic colorectal cancer (mCRC), investigating predictive biomarkers of their prognosis and chemotherapeutic responsiveness is necessary. ...METHODS: This single-center retrospective observational study enrolled 79 …
BACKGROUND: To improve the prognosis of patients with metastatic colorectal cancer (mCRC), investigating predictive biomarkers of the …
Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study.
Liang X, Gui X, Yan Y, Di L, Liu X, Li H, Song G. Liang X, et al. Oncologist. 2024 Feb 2;29(2):e198-e205. doi: 10.1093/oncolo/oyad228. Oncologist. 2024. PMID: 37589217 Free PMC article. Review.
BACKGROUND: Pyrotinib is currently approved for the treatment of HER2-positive advanced breast cancer in China. Data on the overall survival (OS) and efficacy in patients with brain metastasis (BM) remain scarce. This study evaluated the effectiveness of pyrotinib i …
BACKGROUND: Pyrotinib is currently approved for the treatment of HER2-positive advanced breast cancer in China. Data on the ov …
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis.
Michelon I, Vilbert M, Marinho AD, Castro CER, Dacoregio MI, Stecca C, Soares LR, Batista MV, Braga S, Saeed A, Cavalcante L. Michelon I, et al. ESMO Open. 2024 Feb;9(2):102233. doi: 10.1016/j.esmoop.2024.102233. Epub 2024 Feb 5. ESMO Open. 2024. PMID: 38320430 Free PMC article.
BACKGROUND: Trastuzumab deruxtecan (T-DXd) has shown promising results in patients with breast cancer brain metastases (BCBMs). We conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of T-DXd in the human epidermal growth factor …
BACKGROUND: Trastuzumab deruxtecan (T-DXd) has shown promising results in patients with breast cancer brain metastases (BCBMs) …
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
Li Z, Metzger Filho O, Viale G, dell'Orto P, Russo L, Goyette MA, Kamat A, Yardley DA, Gupta Abramson V, Arteaga CL, Spring LM, Chiotti K, Halsey C, Waks AG, King TA, Lester SC, Bellon JR, Winer EP, Spellman PT, Krop IE, Polyak K. Li Z, et al. J Clin Invest. 2024 Feb 1;134(7):e176454. doi: 10.1172/JCI176454. J Clin Invest. 2024. PMID: 38300710 Free PMC article. Clinical Trial.
BACKGROUNDHER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance, in part due to HER2 heterogeneity (HET), is a significant clinical challenge. We previously described that in a phase II neoadjuvant trastuzumab emtansine (T-DM1) …
BACKGROUNDHER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance, in part due to HER2 het …
Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.
Ju J, Gao SL, Wang JY, Sang D, Kang YK, Wang X, Yue J, Shuai Y, Qi YX, Yuan P. Ju J, et al. Thorac Cancer. 2024 Feb;15(6):439-447. doi: 10.1111/1759-7714.15211. Epub 2024 Jan 7. Thorac Cancer. 2024. PMID: 38185807 Free PMC article.
BACKGROUND: Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+) breast cancer exhibits considerable heterogeneity, and it is of great interest whether patients with premenopausal HR+/HER2+ breast cancer treated wit …
BACKGROUND: Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+) breast cancer exhibits c …
Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Dri A, et al. Cancer Treat Rev. 2024 Feb;123:102672. doi: 10.1016/j.ctrv.2023.102672. Epub 2023 Dec 14. Cancer Treat Rev. 2024. PMID: 38118302 Free article. Review.
ADCs had already revolutionized the treatment algorithm of HER2-positive breast cancer. Currently, emergent non-HER2 targeted ADCs are gaining momentum, with special focus on triple-negative disease therapeutic landscape. ...It currently stands as the only non-HER2 …
ADCs had already revolutionized the treatment algorithm of HER2-positive breast cancer. Currently, emergent non-HER2 targeted …
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Lehmann BD, Abramson VG, Dees EC, Shah PD, Ballinger TJ, Isaacs C, Santa-Maria CA, An H, Gonzalez-Ericsson PI, Sanders ME, Newsom KC, Abramson RG, Sheng Q, Hsu CY, Shyr Y, Wolff AC, Pietenpol JA. Lehmann BD, et al. JAMA Oncol. 2024 Feb 1;10(2):193-201. doi: 10.1001/jamaoncol.2023.5424. JAMA Oncol. 2024. PMID: 38095878 Free PMC article.
IMPORTANCE: Agents targeting programmed death ligand 1 (PD-L1) have demonstrated efficacy in triple-negative breast cancer (TNBC) when combined with chemotherapy and are now the standard of care in patients with PD-L1-positive metastatic disease. ...
IMPORTANCE: Agents targeting programmed death ligand 1 (PD-L1) have demonstrated efficacy in triple-negative breast cancer (TN …
Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry.
Ibragimova KIE, Geurts SME, Laczkó D, Meegdes M, Erdkamp F, Heijns JB, Tol J, Vriens BEPJ, Aaldering KNA, Dercksen MW, Pepels MJAE, Peters NAJB, van de Winkel LMH, van de Wouw AJ, de Fallois A, van Kats MACE, Tjan-Heijnen VCG. Ibragimova KIE, et al. Clin Breast Cancer. 2024 Feb;24(2):103-111. doi: 10.1016/j.clbc.2023.10.009. Epub 2023 Nov 2. Clin Breast Cancer. 2024. PMID: 38007349 Free article.
BACKGROUND: This study aims to explore whether first-line pertuzumab use modifies the effect of prior use of (neo-) adjuvant trastuzumab on the PFS of first-line HER2-targeted therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast
BACKGROUND: This study aims to explore whether first-line pertuzumab use modifies the effect of prior use of (neo-) adjuvant trastuzumab on …
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
Martins-Branco D, Kassapian M, Debien V, Caparica R, Eiger D, Dafni U, Andriakopoulou C, El-Abed S, Ellard SL, Izquierdo M, Vicente M, Chumsri S, Piccart-Gebhart M, Moreno-Aspitia A, Knop AS, Lombard J, de Azambuja E. Martins-Branco D, et al. Breast Cancer Res Treat. 2024 Feb;203(3):497-509. doi: 10.1007/s10549-023-07159-9. Epub 2023 Nov 8. Breast Cancer Res Treat. 2024. PMID: 37938495 Free PMC article.
PURPOSE: To assess whether erythropoiesis-stimulating agents (ESA) administration impacts the outcomes of patients with HER2-positive early breast cancer (EBC). METHODS: ALTTO (NCT00490139) patients were categorized by ESA use during adjuvant anti-HER2 treatment. .. …
PURPOSE: To assess whether erythropoiesis-stimulating agents (ESA) administration impacts the outcomes of patients with HER2-positive early …
In Vitro MRS of Cells Treated with Trastuzumab at 1.5 Tesla.
Guz W, Podgórski R, Bober Z, Aebisher D, Truszkiewicz A, Olek M, Machorowska Pieniążek A, Kawczyk-Krupka A, Bartusik-Aebisher D. Guz W, et al. Int J Mol Sci. 2024 Jan 31;25(3):1719. doi: 10.3390/ijms25031719. Int J Mol Sci. 2024. PMID: 38338997 Free PMC article.
The aim of the study was to investigate the effect of Trastuzumab on the MCF-7 and CRL-2314 breast cancer cell lines. Additionally, an attempt was made to optimize magnetic resonance spectroscopy (MRS) for cell culture studies, with particular emphasis on the impact …
The aim of the study was to investigate the effect of Trastuzumab on the MCF-7 and CRL-2314 breast cancer cell lines. Addition …
Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.
Gurrea-Rubio M, Wu Q, Amin MA, Tsou PS, Campbell PL, Amarista CI, Ikari Y, Brodie WD, Mattichak MN, Muraoka S, Randon PM, Lind ME, Ruth JH, Mao-Draayer Y, Ding S, Shen X, Cooney LA, Lin F, Fox DA. Gurrea-Rubio M, et al. Cancer Immunol Immunother. 2024 Jan 27;73(2):34. doi: 10.1007/s00262-023-03578-1. Cancer Immunol Immunother. 2024. PMID: 38280067 Free PMC article.
Here we demonstrate that disrupting the CD6-CD318 axis with UMCD6, an anti-CD6 monoclonal antibody, prolongs survival of mice in xenograft mouse models of human breast and prostate cancer, treated with infusions of human lymphocytes. ...
Here we demonstrate that disrupting the CD6-CD318 axis with UMCD6, an anti-CD6 monoclonal antibody, prolongs survival of mice in xeno …
Detecting Disruption of HER2 Membrane Protein Organization in Cell Membranes with Nanoscale Precision.
Moradi Y, Lee JSH, Armani AM. Moradi Y, et al. ACS Sens. 2024 Jan 26;9(1):52-61. doi: 10.1021/acssensors.3c01437. Epub 2023 Nov 13. ACS Sens. 2024. PMID: 37955934 Free PMC article.
To demonstrate the potential of this approach, the fluorescent molecule sensor is conjugated to a human epidermal growth factor receptor 2 (HER2)-specific antibody and used to investigate the spatiotemporal behavior of HER2 clustering in the membrane of HER2-overexpressing bre
To demonstrate the potential of this approach, the fluorescent molecule sensor is conjugated to a human epidermal growth factor receptor 2 ( …
GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies.
Gellert J, Jäkel A, Danielczyk A, Goletz C, Lischke T, Flechner A, Dix L, Günzl A, Kehler P. Gellert J, et al. Int J Mol Sci. 2024 Jan 24;25(3):1406. doi: 10.3390/ijms25031406. Int J Mol Sci. 2024. PMID: 38338686 Free PMC article.
The tumor-selective expression pattern of TA-MUC1, powerful immune activation and anti-tumor cytotoxicity, long serum half-life and tumor targeting properties, render GT-00AxIL15 a promising candidate for treatment of solid tumors with high medical need, e.g., ovarian, lung and …
The tumor-selective expression pattern of TA-MUC1, powerful immune activation and anti-tumor cytotoxicity, long serum half-life and tumor ta …
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
Qin Y, Song Y, Wang D, Bai O, Feng J, Sun X, Qiu L, Yang J, Yang Y, Wang Z, Hu J, Wang H, Su H, Jin Z, Qian W, Jin C, Zhang M, Yu D, Liu L, Chen G, Li Y, Sun T, Jin J, Bao H, Du X, Zhou H, Fu G, Shi Y. Qin Y, et al. BMC Cancer. 2024 Jan 24;24(1):124. doi: 10.1186/s12885-024-11876-9. BMC Cancer. 2024. PMID: 38267866 Free PMC article. Clinical Trial.
Biosimilar in Breast Cancer: A Narrative Review.
Barman D, Bandyopadhyay T, Talukdar R. Barman D, et al. Cureus. 2024 Jan 23;16(1):e52828. doi: 10.7759/cureus.52828. eCollection 2024 Jan. Cureus. 2024. PMID: 38406112 Free PMC article. Review.
Breast cancer (BC) has been identified as a major public health cancer as it topped the list of most prevalent cancers among women in the last three years. ...Monoclonal antibodies (mAbs), produced through cloning, have demonstrated effectivenes
Breast cancer (BC) has been identified as a major public health cancer as it topped the list of most prevalent cancers
Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.
Wang J, Yu Y, Lin Q, Zhang J, Song C. Wang J, et al. J Cancer Res Clin Oncol. 2024 Jan 20;150(1):21. doi: 10.1007/s00432-023-05530-3. J Cancer Res Clin Oncol. 2024. PMID: 38244085 Free PMC article.
PURPOSE: The numerous first-line treatment regimens for human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) necessitate a comprehensive evaluation to inform clinical decision-making. ...
PURPOSE: The numerous first-line treatment regimens for human epidermal growth factor receptor 2 (HER2)-positive advanced breast c
Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.
Guo L, Cheng H, Liu J, Shao W, Luo L, Zheng W, Sun S, Kong D, Chen C. Guo L, et al. BMC Med Genomics. 2024 Jan 19;17(1):25. doi: 10.1186/s12920-023-01762-x. BMC Med Genomics. 2024. PMID: 38243282 Free PMC article.
BACKGROUND: Breast cancer is the second leading cause of cancer-related death in women, and drug resistance during treatment is a major challenge. ...Ultimately, the study explored the association of APOB gene expression with breast cancer recur …
BACKGROUND: Breast cancer is the second leading cause of cancer-related death in women, and drug resistance during trea …
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA. Andresen NK, et al. J Immunother Cancer. 2024 Jan 19;12(1):e007990. doi: 10.1136/jitc-2023-007990. J Immunother Cancer. 2024. PMID: 38242720 Free PMC article. Clinical Trial.
BACKGROUND: Immune checkpoint inhibitors have shown minimal clinical activity in hormone receptor-positive metastatic breast cancer (HR(+)mBC). Doxorubicin and low-dose cyclophosphamide are reported to induce immune responses and counter regulatory T cells (Tregs). …
BACKGROUND: Immune checkpoint inhibitors have shown minimal clinical activity in hormone receptor-positive metastatic breast cance
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP, Toomey S, Bredin P, Parker I, Mulroe E, Marron J, McLoughlin O, Teiserskiene A, Power C, O'Shea AM, Greally M, Morris PG, Duke D, Hill ADK, Hennessy BT. Dowling GP, et al. BMC Cancer. 2024 Jan 17;24(1):91. doi: 10.1186/s12885-024-11851-4. BMC Cancer. 2024. PMID: 38233810 Free PMC article.
BACKGROUND: The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2 +) breast cancer is to combine systemic chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab. ...Trastuzumab deruxtecan (T-DXd) is an HER2-directed anti …
BACKGROUND: The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2 +) breast cancer is to c …
Production and characterization of single-chain variable fragment antibodies targeting the breast cancer tumor marker nectin-4.
Liu CH, Leu SJ, Lee CH, Lin CY, Wang WC, Tsai BY, Lee YC, Chen CL, Yang YY, Lin LT. Liu CH, et al. Front Immunol. 2024 Jan 15;14:1292019. doi: 10.3389/fimmu.2023.1292019. eCollection 2023. Front Immunol. 2024. PMID: 38288120 Free PMC article.
BACKGROUND: Nectin-4 is a novel biomarker overexpressed in various types of cancer, including breast cancer, in which it has been associated with poor prognosis. ...The present study aims to produce nectin-4-specific single-chain variable fragment (scFv) a
BACKGROUND: Nectin-4 is a novel biomarker overexpressed in various types of cancer, including breast cancer, in which i …
Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo.
Kuchukulla RR, Hwang I, Kim SH, Kye Y, Park N, Cha H, Moon S, Chung HW, Lee C, Kong G, Hur W. Kuchukulla RR, et al. Eur J Med Chem. 2024 Jan 15;264:116014. doi: 10.1016/j.ejmech.2023.116014. Epub 2023 Dec 1. Eur J Med Chem. 2024. PMID: 38061230 Free article.
Compound 32e potently inhibited CDK12/cyclinK with IC(50) = 3 nM, and suppressed the growth of the both trastuzumab-sensitive and trastuzumab-resistant HER2-positive breast cancer cell lines (GI(50)'s = 9-21 nM), which is superior to a potent, clinical pan-CDK inhib …
Compound 32e potently inhibited CDK12/cyclinK with IC(50) = 3 nM, and suppressed the growth of the both trastuzumab-sensitive and trastuzuma …
Exploring the Spectrum of VEGF Inhibitors' Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice.
Santorsola M, Capuozzo M, Nasti G, Sabbatino F, Di Mauro A, Di Mauro G, Vanni G, Maiolino P, Correra M, Granata V, Gualillo O, Berretta M, Ottaiano A. Santorsola M, et al. Cancers (Basel). 2024 Jan 13;16(2):350. doi: 10.3390/cancers16020350. Cancers (Basel). 2024. PMID: 38254839 Free PMC article. Review.
The use of Vascular Endothelial Growth Factor inhibitors (VEGFi) has become prevalent in the field of medicine, given the high incidence of various pathological conditions necessitating VEGF inhibition within the general population. These conditions encompass a range of advanced …
The use of Vascular Endothelial Growth Factor inhibitors (VEGFi) has become prevalent in the field of medicine, given the high incidence of …
Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use.
Li Y, Pond G, McWhirter E. Li Y, et al. Curr Oncol. 2024 Jan 11;31(1):425-435. doi: 10.3390/curroncol31010028. Curr Oncol. 2024. PMID: 38248113 Free PMC article.
METHODS: A retrospective cohort review was completed that included cancer patients seen at the Juravinski Cancer Centre who received at least one dose of ipilimumab and nivolumab from 2018 to 2022. ...Out of 123 patients, 72 (59%) had melanoma, 50/123 (41%) had rena …
METHODS: A retrospective cohort review was completed that included cancer patients seen at the Juravinski Cancer Centre who re …
Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial.
Ding N, Pang J, Liu X, He X, Zhou W, Xie H, Feng J, Wang G, Tang J, Cao J, He L, He Y, Wang S, Xiao Z. Ding N, et al. Breast Cancer Res. 2024 Jan 11;26(1):9. doi: 10.1186/s13058-023-01761-x. Breast Cancer Res. 2024. PMID: 38212845 Free PMC article.
PURPOSE: This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab. ...
PURPOSE: This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic b
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.
Lewis GD, Li G, Guo J, Yu SF, Fields CT, Lee G, Zhang D, Dragovich PS, Pillow T, Wei B, Sadowsky J, Leipold D, Wilson T, Kamath A, Mamounas M, Lee MV, Saad O, Choeurng V, Ungewickell A, Monemi S, Crocker L, Kalinsky K, Modi S, Jung KH, Hamilton E, LoRusso P, Krop I, Schutten MM, Commerford R, Sliwkowski MX, Cho E. Lewis GD, et al. Nat Commun. 2024 Jan 11;15(1):466. doi: 10.1038/s41467-023-44533-z. Nat Commun. 2024. PMID: 38212321 Free PMC article. Clinical Trial.
Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxtecan. ...A dose-escalation study (ClinicalTrials.gov: NCT03451162) in patients with HER2-positive metastatic breast cancer, wit …
Approved antibody-drug conjugates (ADCs) for HER2-positive breast cancer include trastuzumab emtansine and trastuzumab deruxte …
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis.
Gammelgaard OL, Terp MG, Kirkin AF, Johansen S, Traynor S, Vever H, Guldberg P, Kodahl AR, Gjerstorff MF, Ditzel HJ. Gammelgaard OL, et al. Mol Cancer. 2024 Jan 6;23(1):6. doi: 10.1186/s12943-023-01914-8. Mol Cancer. 2024. PMID: 38184565 Free PMC article.
METHODS: Immunodeficient mice were challenged with triple-negative breast cancer cell lines or patient-derived xenografts (PDX) and treated with allogeneic or autologous ALECSAT cells with and without anti-PDL1 therapy to assess the capacity of ALECSAT cells to inhi …
METHODS: Immunodeficient mice were challenged with triple-negative breast cancer cell lines or patient-derived xenografts (PDX …
Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs.
Ke CH, Lin CN, Lin CS. Ke CH, et al. Int J Mol Sci. 2024 Jan 5;25(2):732. doi: 10.3390/ijms25020732. Int J Mol Sci. 2024. PMID: 38255807 Free PMC article. Review.
Breast cancer (BC) is the most frequent cancer in women. In female dogs, canine mammary gland tumor (CMT) is also the leading neoplasm. ...For hormone receptor-expressing BCs, the first medical intervention is hormone therapy. Monoclonal antibodies
Breast cancer (BC) is the most frequent cancer in women. In female dogs, canine mammary gland tumor (CMT) is also the l
Adjuvant trastuzumab for triple-positive breast cancer with chronic renal failure: A case report and review of literature.
En W, Long Y. En W, et al. Medicine (Baltimore). 2024 Jan 5;103(1):e36278. doi: 10.1097/MD.0000000000036278. Medicine (Baltimore). 2024. PMID: 38181290 Free PMC article. Review.
RATIONALE: Although the occurrence of combined renal insufficiency among patients with breast cancer is even rarer, it poses a significant challenge in the treatment of these patients. ...CONCLUSION: We report a case of triple-positive breast cancer in …
RATIONALE: Although the occurrence of combined renal insufficiency among patients with breast cancer is even rarer, it poses a …
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients.
Tolaney SM, Goel S, Nadal J, Denys H, Borrego MR, Litchfield LM, Liu J, Appiah AK, Chen Y, André F. Tolaney SM, et al. Clin Cancer Res. 2024 Jan 5;30(1):39-49. doi: 10.1158/1078-0432.CCR-23-1209. Clin Cancer Res. 2024. PMID: 37906649 Free PMC article. Clinical Trial.
PURPOSE: The monarcHER trial has shown that abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, combined with fulvestrant and trastuzumab, improves progression-free survival (PFS) in hormone receptor-positive (HR+), HER2-positive (HER2+) advanced breast cancer
PURPOSE: The monarcHER trial has shown that abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, combined with fulvestrant and trastuzu …
Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.
Wilkerson AD, Parthasarathy PB, Stabellini N, Mitchell C, Pavicic PG Jr, Fu P, Rupani A, Husic H, Rayman PA, Swaidani S, Abraham J, Budd GT, Moore H, Al-Hilli Z, Ko JS, Baar J, Chan TA, Alban T, Diaz-Montero CM, Montero AJ. Wilkerson AD, et al. Clin Cancer Res. 2024 Jan 5;30(1):82-93. doi: 10.1158/1078-0432.CCR-23-1349. Clin Cancer Res. 2024. PMID: 37882661 Free PMC article. Clinical Trial.
PURPOSE: A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), safet …
PURPOSE: A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple-negative breast
A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer.
Yang JX, Yang YQ, Hu WY, Yang L, Wu J, Wen XX, Yu J, Huang ML, Xu DD, Tie DC, Wang L, Li FF, Li NL. Yang JX, et al. Oncologist. 2024 Jan 5;29(1):e15-e24. doi: 10.1093/oncolo/oyad160. Oncologist. 2024. PMID: 37279780 Free PMC article. Clinical Trial.
BACKGROUND: Neoadjuvant trastuzumab/pertuzumab (HP) plus chemotherapy for HER2-positive breast cancer (BC) achieved promising efficacy. The additional cardiotoxicity still existed. ...Ninety-five (99.0%) patients received 8 cycles of neoadjuvant therapy and all unde …
BACKGROUND: Neoadjuvant trastuzumab/pertuzumab (HP) plus chemotherapy for HER2-positive breast cancer (BC) achieved promising …
NK cell-triggered CCL5/IFNgamma-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.
Santana-Hernández S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera-Bel J, Menendez S, Arpí O, Bermejo B, Martínez MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A. Santana-Hernández S, et al. J Exp Clin Cancer Res. 2024 Jan 3;43(1):10. doi: 10.1186/s13046-023-02918-4. J Exp Clin Cancer Res. 2024. PMID: 38167224 Free PMC article.
Tumor-infiltrating Natural Killer (TI-NK) cells can predict the efficacy of HER2-targeted antibodies independently from clinicopathological factors in primary HER2-positive breast cancer patients. ...Findings were analysed in clinical samples (tumor and serum …
Tumor-infiltrating Natural Killer (TI-NK) cells can predict the efficacy of HER2-targeted antibodies independently from clinicopathol …
Fat Body Mass and Vertebral Fracture Progression in Women With Breast Cancer.
Cosentini D, Pedersini R, Di Mauro P, Zamparini M, Schivardi G, Rinaudo L, Di Meo N, Delbarba A, Cappelli C, Laganà M, Alberti A, Baronchelli M, Guerci G, Laini L, Grisanti S, Simoncini EL, Farina D, Mazziotti G, Berruti A; Bone Health Group of the ASST Spedali Civili, Brescia. Cosentini D, et al. JAMA Netw Open. 2024 Jan 2;7(1):e2350950. doi: 10.1001/jamanetworkopen.2023.50950. JAMA Netw Open. 2024. PMID: 38198137 Free PMC article.
IMPORTANCE: Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures despite treatment with bone-active drugs. ...DESIGN, SETTING, AND PARTICIPANTS: For this prospective, single-center, cohort study, 237 patients …
IMPORTANCE: Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures desp …
Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Masuda Y, Yamashita S, Nakayama Y, Shimizu R, Konishi M. Masuda Y, et al. Biol Pharm Bull. 2024;47(4):840-847. doi: 10.1248/bpb.b23-00802. Biol Pharm Bull. 2024. PMID: 38616114 Free article.
Trastuzumab, an anti-HER2 monoclonal antibody, is the mainstay treatment for of HER2-positive breast cancer. ...In this study, we examined the effect of MD-Fraction on trastuzumab treatment of HER2-positive breast cancer. MD-Fraction did not dir …
Trastuzumab, an anti-HER2 monoclonal antibody, is the mainstay treatment for of HER2-positive breast cancer. ...In this …
Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer.
Rodriguez GF, Shah A, Maderal AD. Rodriguez GF, et al. Breast Dis. 2024;43(1):61-64. doi: 10.3233/BD-230053. Breast Dis. 2024. PMID: 38578876 Free PMC article.
BACKGROUND: Tucatinib is a tyrosine kinase inhibitor currently used in salvage therapy for human epidermal growth factor receptor 2 (HER2)-positive breast and colorectal cancer. The use of tucatinib alone or in combination with ado-trastuzumab emtansine (T-DM1) in t …
BACKGROUND: Tucatinib is a tyrosine kinase inhibitor currently used in salvage therapy for human epidermal growth factor receptor 2 (HER2)-p …
Outcomes of the patients with metastatic male breast cancer.
Dogan I, Khanmammadov N, Ozkurt S, Aydiner A, Saip P. Dogan I, et al. J Cancer Res Ther. 2024 Jan 1;20(1):98-102. doi: 10.4103/jcrt.jcrt_1829_22. Epub 2023 Apr 8. J Cancer Res Ther. 2024. PMID: 38554305 Free article.
BACKGROUND: The goal of this research is to investigate the clinical characteristics and prognosis of men with metastatic breast cancer (mMBC). METHODS: A retrospective analysis of the data of 28 patients was conducted. ...
BACKGROUND: The goal of this research is to investigate the clinical characteristics and prognosis of men with metastatic breast c
Anti-IL-8 monoclonal antibodies inhibits the autophagic activity and cancer stem cells maintenance within breast cancer tumor microenvironment.
Abou Shousha S, Osman EM, Baheeg S, Shahine Y. Abou Shousha S, et al. Breast Dis. 2024;43(1):37-49. doi: 10.3233/BD-230052. Breast Dis. 2024. PMID: 38552109 Free PMC article.
BACKGROUND: Breast cancer tumor microenvironment (TME) is a promising target for immunotherapy. ...CONCLUSIONS: Anti-IL-8 monoclonal antibody exhibits promising immunotherapeutic properties through targeting both autophagy and CSCs maintenance within breas
BACKGROUND: Breast cancer tumor microenvironment (TME) is a promising target for immunotherapy. ...CONCLUSIONS: Anti-IL-8 m
Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study.
Nonomiya Y, Nakayama I, Kobayashi K, Amakawa Y, Shibata N, Soejima A, Kawakami K, Shimizu H, Takahari D, Kawai S, Hara F, Takano T, Yamaguchi K, Yamaguchi M. Nonomiya Y, et al. Biol Pharm Bull. 2024;47(2):411-416. doi: 10.1248/bpb.b23-00695. Biol Pharm Bull. 2024. PMID: 38346748 Free article. Review.
Therefore, we assessed the adverse event (AE) profiles of T-DXd in patients with advanced gastric or breast cancer to provide guidance for appropriate management. This retrospective study was conducted at the Cancer Institute Hospital of the Japanese Foundati …
Therefore, we assessed the adverse event (AE) profiles of T-DXd in patients with advanced gastric or breast cancer to provide …
Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer.
Senín LD, Pancorbo DM, Garcés MYR, Santos-Rubio MD, Calero JB. Senín LD, et al. Curr Oncol. 2024 Jan 1;31(1):250-259. doi: 10.3390/curroncol31010016. Curr Oncol. 2024. PMID: 38248101 Free PMC article.
All patients with breast cancer treated with denosumab (January 2011-December 2022) were included. ...CONCLUSIONS: These results suggest that the incidence of MRONJ in patients with metastatic breast cancer treated with denosumab is higher, and the ons …
All patients with breast cancer treated with denosumab (January 2011-December 2022) were included. ...CONCLUSIONS: These resul …
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial.
Reddy N, Reddy P, Ranpura A, Maharaj N, Arora R, Mamillapalli G, Adhav AS, Diwan AK, Manikhas A, Krasnozhon D. Reddy N, et al. JCO Glob Oncol. 2024 Jan;10:e2200328. doi: 10.1200/GO.22.00328. JCO Glob Oncol. 2024. PMID: 38237093 Free PMC article. Clinical Trial.
The present study was conducted to evaluate efficacy, safety, pharmacokinetics (PKs), and immunogenicity of DRL_TZ in comparison with the reference medicinal product (RMP) along with concomitant weekly paclitaxel in patients with human epidermal growth factor receptor 2 (HER2)-po …
The present study was conducted to evaluate efficacy, safety, pharmacokinetics (PKs), and immunogenicity of DRL_TZ in comparison with the re …
Combination chemotherapy with trastuzumab in early-stage breast cancer: a meta-analysis and Bayesian decision analysis of different treatment regimens.
Liu Q. Liu Q. Eur Rev Med Pharmacol Sci. 2024 Jan;28(1):231-241. doi: 10.26355/eurrev_202401_34908. Eur Rev Med Pharmacol Sci. 2024. PMID: 38235874 Free article.
OBJECTIVE: HER2-positive breast cancer is a high-risk malignant tumor, and trastuzumab is an effective targeted therapy drug, but its optimal duration remains uncertain. ...CONCLUSIONS: It is recommended to use 12 months of trastuzumab combination chemotherapy as th …
OBJECTIVE: HER2-positive breast cancer is a high-risk malignant tumor, and trastuzumab is an effective targeted therapy drug, …
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.
Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El Saghir NS, Arun BK. Al Sukhun S, et al. JCO Glob Oncol. 2024 Jan;10:e2300285. doi: 10.1200/GO.23.00285. JCO Glob Oncol. 2024. PMID: 38206277 Free PMC article.
PURPOSE: To guide clinicians and policymakers in three global resource-constrained settings on treating patients with metastatic breast cancer (MBC) when Maximal setting-guideline recommended treatment is unavailable. ...
PURPOSE: To guide clinicians and policymakers in three global resource-constrained settings on treating patients with metastatic breast
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Lin CC, Garralda E, Schöffski P, Hong DS, Siu LL, Martin M, Maur M, Hui R, Soo RA, Chiu J, Zhang T, Ma B, Kyi C, Tan DS, Cassier PA, Sarantopoulos J, Weickhardt A, Carvajal RD, Spratlin J, Esaki T, Rolland F, Akerley W, Deschler-Baier B, Rispoli L, Samant TS, Chowdhury NR, Gusenleitner D, Kwak EL, Askoxylakis V, De Braud F. Lin CC, et al. Oncoimmunology. 2023 Dec 20;13(1):2290787. doi: 10.1080/2162402X.2023.2290787. eCollection 2024. Oncoimmunology. 2023. PMID: 38170160 Free PMC article. Clinical Trial.
Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination treatment in patients with select …
Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab …
HER2-targeted therapies for salivary gland cancers.
Filippini DM, Pagani R, Tober N, Lorini L, Riefolo M, Molinari G, Burato A, Alfieri S, Bossi P, Presutti L. Filippini DM, et al. Oral Oncol. 2024 Jan;148:106612. doi: 10.1016/j.oraloncology.2023.106612. Epub 2023 Nov 27. Oral Oncol. 2024. PMID: 38016228 Free article. Review.
The efficacy and safety of anti-HER2 were firstly evaluated in patients affected with other solid tumors, mostly breast and gastric cancers. For SGCs the literature is mainly comprised of case reports or case series and small clinical trials. ...
The efficacy and safety of anti-HER2 were firstly evaluated in patients affected with other solid tumors, mostly breast and gastric c …
Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H(2) Mab-77-mG(2a) -f.
Tanaka T, Suzuki H, Ohishi T, Kaneko MK, Kato Y. Tanaka T, et al. Cancer Sci. 2024 Jan;115(1):298-309. doi: 10.1111/cas.16008. Epub 2023 Nov 9. Cancer Sci. 2024. PMID: 37942574 Free PMC article.
Breast cancer patients with high levels of human epidermal growth factor receptor 2 (HER2) expression have worse clinical outcomes. Anti-HER2 monoclonal antibody (mAb) is the most important therapeutic modality for HER2-positive breast cancer. .
Breast cancer patients with high levels of human epidermal growth factor receptor 2 (HER2) expression have worse clinical outc
Direct competitive assay for HER2 detection in human plasma using Bloch surface wave-based biosensors.
Pileri T, Sinibaldi A, Occhicone A, Danz N, Giordani E, Allegretti M, Sonntag F, Munzert P, Giacomini P, Michelotti F. Pileri T, et al. Anal Biochem. 2024 Jan 1;684:115374. doi: 10.1016/j.ab.2023.115374. Epub 2023 Oct 31. Anal Biochem. 2024. PMID: 37914005 Free article.
The overexpression and/or amplification of the HER2/neu oncogene has been proposed as a prognostic marker in breast cancer. The detection of the related peptide HER2 remains a grand challenge in cancer diagnosis and for therapeutic decision-making. ...
The overexpression and/or amplification of the HER2/neu oncogene has been proposed as a prognostic marker in breast cancer. Th …
Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.
Williamson M, Press DJ, Hansen SA, Tomar A, Jhuti GS, Revil C, Gururaj K. Williamson M, et al. Breast Cancer. 2024 Jan;31(1):84-95. doi: 10.1007/s12282-023-01514-w. Epub 2023 Nov 1. Breast Cancer. 2024. PMID: 37907759 Free PMC article.
PURPOSE: Treating early-stage breast cancer (eBC) may delay or prevent subsequent metastatic breast cancer (mBC). ...METHODS: An epidemiological prediction model using data from national cancer registries, observational studies, and clinical tri …
PURPOSE: Treating early-stage breast cancer (eBC) may delay or prevent subsequent metastatic breast cancer (mBC) …
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Meric-Bernstam F, et al. J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23. J Clin Oncol. 2024. PMID: 37870536 Free PMC article. Clinical Trial.
PURPOSE: Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. ...
PURPOSE: Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expres …
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.
Gu S, Dusza S, Quigley E, Haliasos H, Markova A, Marchetti M, Moy AP, Dang C, Modi S, Lake D, Noor S, Lacouture ME. Gu S, et al. Breast Cancer Res Treat. 2024 Jan;203(2):271-280. doi: 10.1007/s10549-023-07143-3. Epub 2023 Oct 13. Breast Cancer Res Treat. 2024. PMID: 37833451 Free PMC article.
PURPOSE: The combination of trastuzumab and pertuzumab (HP) as part of a taxane-based regimen has shown benefit in the adjuvant and metastatic HER2 + breast cancer setting. In the CLEOPATRA trial, pruritus was reported in 11-17.6% of patients. ...METHODS: A retrospe …
PURPOSE: The combination of trastuzumab and pertuzumab (HP) as part of a taxane-based regimen has shown benefit in the adjuvant and metastat …
Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.
Zhu Y, Yang Q, Liu K, Cao H, Zhu H. Zhu Y, et al. J Gynecol Oncol. 2024 Jan;35(1):e2. doi: 10.3802/jgo.2024.35.e2. Epub 2023 Jul 5. J Gynecol Oncol. 2024. PMID: 37477106 Free PMC article.
OBJECTIVE: The PAOLA-1 trial (NCT02477644) reported final survival benefit associated with olaparib plus bevacizumab maintenance treatment of patients with advanced ovarian cancer (AOC) based on molecular status. Our aimed to compare the cost-effectiveness of olaparib plus …
OBJECTIVE: The PAOLA-1 trial (NCT02477644) reported final survival benefit associated with olaparib plus bevacizumab maintenance treatment o …
Understanding How Monoclonal Antibodies Work.
Malik B, Ghatol A. Malik B, et al. 2023 Jun 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jun 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 34283484 Free Books & Documents.
Modern-day medicine has been revolutionized to be personalized and specific based on individualized specific disease characteristics. Monoclonal antibodies (mAbs) are a prime example of personalized therapeutics enabled by advances in our knowledge of immunology, mo …
Modern-day medicine has been revolutionized to be personalized and specific based on individualized specific disease characteristics. Mon
Cancer Chemotherapy.
Amjad MT, Chidharla A, Kasi A. Amjad MT, et al. 2023 Feb 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Feb 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 33232037 Free Books & Documents.
The successful management of choriocarcinoma and leukemias with methotrexate led to further investigations in cancer chemotherapy. And drugs like thiopurines (e.g., 6-mercaptopurine), 5-fluorouracil came into the forefront of cancer treatment. ...With an increased u …
The successful management of choriocarcinoma and leukemias with methotrexate led to further investigations in cancer chemotherapy. An …
Precision Immunotherapy Utilizing Adapter CAR-T Cells (AdCAR-T) in Metastatic Breast Cancer Leads to Target Specific Lysis.
Önder CE, Moustafa-Oglou M, Schröder SM, Hartkopf AD, Koch A, Seitz CM. Önder CE, et al. Cancers (Basel). 2023 Dec 29;16(1):168. doi: 10.3390/cancers16010168. Cancers (Basel). 2023. PMID: 38201595 Free PMC article.
A frequent symptom of metastasized breast cancer (BC) includes the development of malignant pleural effusion (MPE), which contains malignant cells derived from the primary tumor site. ...Based on an individual antigen expression pattern, patient-derived organoids we …
A frequent symptom of metastasized breast cancer (BC) includes the development of malignant pleural effusion (MPE), which cont …
Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential.
Chamorro DF, Somes LK, Hoyos V. Chamorro DF, et al. Cancers (Basel). 2023 Dec 26;16(1):124. doi: 10.3390/cancers16010124. Cancers (Basel). 2023. PMID: 38201551 Free PMC article. Review.
Breast cancer remains a significant health challenge, and novel treatment approaches are critically needed. This review presents an in-depth analysis of engineered adoptive T-cell therapies (E-ACTs), an innovative frontier in cancer immunotherapy, focusing on
Breast cancer remains a significant health challenge, and novel treatment approaches are critically needed. This review presen
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
Feng Y, Lee J, Yang L, Hilton MB, Morris K, Seaman S, Edupuganti VVSR, Hsu KS, Dower C, Yu G, So D, Bajgain P, Zhu Z, Dimitrov DS, Patel NL, Robinson CM, Difilippantonio S, Dyba M, Corbel A, Basuli F, Swenson RE, Kalen JD, Suthe SR, Hussain M, Italia JS, Souders CA, Gao L, Schnermann MJ, St Croix B. Feng Y, et al. Cell Rep. 2023 Dec 26;42(12):113503. doi: 10.1016/j.celrep.2023.113503. Epub 2023 Nov 28. Cell Rep. 2023. PMID: 38019654 Free PMC article.
CD276/B7-H3 represents a promising target for cancer therapy based on widespread overexpression in both cancer cells and tumor-associated stroma. ...Here, we describe the development of a modified talirine PBD-based fully human CD276 ADC, called m276-SL-PBD, that is …
CD276/B7-H3 represents a promising target for cancer therapy based on widespread overexpression in both cancer cells and tumor …
Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.
Lee J, Turetsky J, Nasri E, Rogers SC. Lee J, et al. BMJ Case Rep. 2023 Dec 23;16(12):e255916. doi: 10.1136/bcr-2023-255916. BMJ Case Rep. 2023. PMID: 38142057 Free PMC article.
Immunohistochemistry of our patient's malignant cytology sample showed loss of Breast Cancer Gene 1-associated protein-1 expression (BAP1). The patient had synchronous diagnoses of primary squamous cell carcinoma of the anus, benign schwannoma and meningioma. ...
Immunohistochemistry of our patient's malignant cytology sample showed loss of Breast Cancer Gene 1-associated protein-1 expre …
Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.
Sanz-Álvarez M, Luque M, Morales-Gallego M, Cristóbal I, Ramírez-Merino N, Rangel Y, Izarzugaza Y, Eroles P, Albanell J, Madoz-Gúrpide J, Rojo F. Sanz-Álvarez M, et al. Int J Mol Sci. 2023 Dec 22;25(1):207. doi: 10.3390/ijms25010207. Int J Mol Sci. 2023. PMID: 38203378 Free PMC article.
The combination of trastuzumab and pertuzumab as first-line therapy in patients with HER2-positive breast cancer has shown significant clinical benefits compared to trastuzumab alone. ...Finally, proteomic analysis confirmed a significant change in the abundance pat …
The combination of trastuzumab and pertuzumab as first-line therapy in patients with HER2-positive breast cancer has shown sig …
Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study.
Chen G, Gu X, Xue J, Zhang X, Yu X, Zhang Y, Li A, Zhao Y, He G, Tang M, Xing F, Yin J, Bian X, Han Y, Cao S, Liu C, Jiang X, Zhang K, Xia Y, Li H, Niu N, Liu C; Northeastern Clinical Research Alliance of Oncology (NCRAO). Chen G, et al. Elife. 2023 Dec 22;12:e91737. doi: 10.7554/eLife.91737. Elife. 2023. PMID: 38131294 Free PMC article. Clinical Trial.
With proven effective but suboptimal effect of ICI and chemotherapy in triple-negative breast cancer (TNBC), we designed a pilot study to explore the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT) plus adebrelimab and chemotherapy in TNBC p …
With proven effective but suboptimal effect of ICI and chemotherapy in triple-negative breast cancer (TNBC), we designed a pil …
The Relationship between Trop-2, Chemotherapeutic Drugs, and Chemoresistance.
Koltai T, Fliegel L. Koltai T, et al. Int J Mol Sci. 2023 Dec 20;25(1):87. doi: 10.3390/ijms25010087. Int J Mol Sci. 2023. PMID: 38203255 Free PMC article. Review.
The development of antibody conjugate drugs (ACD) centered on anti-Trop-2 monoclonal antibodies opened the gates for the treatment of some tumors resistant to classic chemotherapies. Advanced urothelial tumors and breast cancer were among the first mal …
The development of antibody conjugate drugs (ACD) centered on anti-Trop-2 monoclonal antibodies opened the gates for the treat …
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez RH, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg DW, Sellami D, Yonemori K. Krop IE, et al. J Clin Oncol. 2023 Dec 20;41(36):5550-5560. doi: 10.1200/JCO.23.00882. Epub 2023 Oct 6. J Clin Oncol. 2023. PMID: 37801674 Free PMC article. Clinical Trial.
Efficacy results are reported across clinical subtypes: hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer (n = 113; objective response rate [ORR], 30.1%; median progression-free survival [mPFS], 7.4 month …
Efficacy results are reported across clinical subtypes: hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (H …
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.
Liu L, Zhu M, Wang Y, Li M, Gu Y. Liu L, et al. World J Surg Oncol. 2023 Dec 19;21(1):389. doi: 10.1186/s12957-023-03266-5. World J Surg Oncol. 2023. PMID: 38114991 Free PMC article.
METHODS: A total of 138 HER2-positive breast cancer patients who received neoadjuvant therapy and underwent surgery were included. ...CONCLUSION: The efficacy and safety of the P + EC-TH regimen were verified by this study. The HER2-positive breast cancer
METHODS: A total of 138 HER2-positive breast cancer patients who received neoadjuvant therapy and underwent surgery were inclu …
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, Iivanainen S, Shetty S, Ma YT, Graham DM, Arora SP, Jaakkola P, Yap C, Xiang Y, Mandelin J, Karvonen MK, Jalkanen J, Karaman S, Koivunen JP, Minchom A, Hollmén M, Bono P. Rannikko JH, et al. Cell Rep Med. 2023 Dec 19;4(12):101307. doi: 10.1016/j.xcrm.2023.101307. Epub 2023 Dec 5. Cell Rep Med. 2023. PMID: 38056464 Free PMC article. Clinical Trial.
Disease control (DC) rates of 25%-40% are observed in cutaneous melanoma, gastric, hepatocellular, estrogen receptor-positive breast, and biliary tract cancers. DC associates with improved survival in a landmark analysis and correlates with high pre-treatment intratumoral …
Disease control (DC) rates of 25%-40% are observed in cutaneous melanoma, gastric, hepatocellular, estrogen receptor-positive breast, …
Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy.
Yang Y, Wu H, Yang Y, Kang Y, He R, Zhou B, Guo H, Zhang J, Li J, Ge C, Wang T. Yang Y, et al. Mol Ther Oncolytics. 2023 Nov 4;31:100747. doi: 10.1016/j.omto.2023.100747. eCollection 2023 Dec 19. Mol Ther Oncolytics. 2023. PMID: 38046893 Free PMC article.
CD47 and its receptor signal regulatory protein alpha (SIRPalpha) act as a dominant antiphagocytic, "don't eat me" signal. Recent studies reveal CD24 as a novel target for cancer immunotherapy by macrophages in ovarian cancer and breast cancer. ...
CD47 and its receptor signal regulatory protein alpha (SIRPalpha) act as a dominant antiphagocytic, "don't eat me" signal. Recent studies re …
Generation and Characterization of SORT1-Targeted Antibody-Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor.
Zhuang W, Zhang W, Xie L, Wang L, Li Y, Wang Z, Zhang A, Qiu H, Feng J, Zhang B, Hu Y. Zhuang W, et al. Int J Mol Sci. 2023 Dec 18;24(24):17631. doi: 10.3390/ijms242417631. Int J Mol Sci. 2023. PMID: 38139459 Free PMC article.
Antibody-drug conjugates (ADCs) have greatly improved the outcomes of advanced breast tumors. However, the treatment of breast tumors with existing ADCs is still hindered by many issues, such as tumor antigen heterogeneity and drug resistance. ...Sortilin-1 (SORT1) …
Antibody-drug conjugates (ADCs) have greatly improved the outcomes of advanced breast tumors. However, the treatment of breast
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective.
Bradbury M, Savard MF, Vandermeer L, Clemons L, Pond G, Hilton J, Clemons M, McGee S. Bradbury M, et al. Curr Oncol. 2023 Dec 14;30(12):10477-10487. doi: 10.3390/curroncol30120763. Curr Oncol. 2023. PMID: 38132397 Free PMC article.
Despite evidence from clinical trials showing the efficacy of shorter durations of therapy, most HER2-positive early breast cancer (EBC) patients receive a year of anti-HER2 therapy. ...
Despite evidence from clinical trials showing the efficacy of shorter durations of therapy, most HER2-positive early breast cancer
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
Seo J, Koh J, Lee DW, Kim J, Ryu HS, Lee KH, Kim TY, Im SA. Seo J, et al. Breast Cancer Res. 2023 Dec 14;25(1):154. doi: 10.1186/s13058-023-01746-w. Breast Cancer Res. 2023. PMID: 38098054 Free PMC article.
However, its association with survival outcomes in advanced HER2-positive breast cancer treated with dual HER2-blockade remains unexplored. METHODS: This is a single-center retrospective study of patients with advanced HER2-positive breast cancer treat …
However, its association with survival outcomes in advanced HER2-positive breast cancer treated with dual HER2-blockade remain …
Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial.
Zheng Y, Cao WM, Shao X, Shi Y, Cai L, Chen W, Liu J, Shen P, Chen Y, Wang X, Li H, Li M, Chen Z, Wang X. Zheng Y, et al. Nat Commun. 2023 Dec 14;14(1):8314. doi: 10.1038/s41467-023-44140-y. Nat Commun. 2023. PMID: 38097605 Free PMC article. Clinical Trial.
The role of pyrotinib in the treatment of HER2-positive metastatic breast cancer (MBC) has been well-established. This multicenter, single-arm phase II trial (NCT03876587) aimed to assess the benefit of pyrotinib plus docetaxel as a first-line treatment for HER2-pos …
The role of pyrotinib in the treatment of HER2-positive metastatic breast cancer (MBC) has been well-established. This multice …
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada.
Gambaro K, Groleau M, McNamara S, Awan A, Salem M, Abdelsalam M, St-Hilaire E, Vincent F, Carrier J, MacKay H, Provencher L, Boudreau D, Hamilou Z, Saad F, Ferrario C, Batist G, Marques M. Gambaro K, et al. J Pharm Pharm Sci. 2023 Dec 13;26:12078. doi: 10.3389/jpps.2023.12078. eCollection 2023. J Pharm Pharm Sci. 2023. PMID: 38152647 Free PMC article.
There is an increasing demand for real-world data pertaining to the usage of cancer treatments, especially in settings where no standard treatment is specifically recommended. This study presents the first real-world analysis of third-line treatment patterns in HER2-positi …
There is an increasing demand for real-world data pertaining to the usage of cancer treatments, especially in settings where no stand …